Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
From the other board (H/T Songbirdlive):
Found the following on Dr. Faro's linkedin page:
Jon Faro - 1st
Joins Board of Directors
Nanologix - Rush Medical College of Rush
University Medical Center
Houston, Texas.
This is great news. Must have just recently developed.
Maybe the Company can include this in one of their next updates.
I agree. I had assumed that poster was doing all the buying of late. I included the entire post as that's just something I prefer to do. I apologize for any confusion.
EI, I assumed it was related to this post from another board:
Just to let you know. I believe in the company and have been buying up shares. I am a real person and rarely post. Don't have much time and have no reason to try to manipulate anything. Have never sold one share. Due to it's current price I moved it all into my Roth and I would advise everyone to do that if you can and have one.
I like the company because of what happened to my mother and I know that this product would have changed the quality of her life. You can find that story posted back sometime ago.
All I know is that my order to buy has not totally been filled. So based on that fact people are holding onto their shares. I just keep praying for the company and those in control that they would make right decisions for all of us
My advise is that those of you who are on the frustrated negative side spend your time on your knees in prayer. That would have a much greater impact on our situation than what I am reading here.
We all make decisions to invest in something for our own reasons. If you think that it is time to sell then go ahead. There are plenty of us out here who will buy your shares. If not there was a song I remember from my early teens that I highly recommend. Frankie Valli & The Four Seasons Recorded it, "Silence is golden." From my perspective I would appreciate it.
If you have real information that can be verified then by all means go ahead post. If not, please don't waste everyone's time. Just keep quiet.
(And thank you Charlie. EOM)
Micronex Systems was nice enough to send me a message on FB saying that they've corrected the URL and thanked me in the process. Best of luck to them!
Thanks Charlie. EOM
I am less concerned about the page's functionality and more concerned that a prospective client will look at the page and think to themselves that the people running the show are bumbling fools.
It's in the URL. EOM
I've message them and posted on their page about the FB site being facebook.com/MiconexSystems. My PM did not get a response and my post was deleted.
To me this seems like the best way to maximize being informative and transparent, and it would also be an efficient use of time versus potentially responding to similar questions via e-mail or on the phone. Cheers on the forward thinking.
LOL, yeah, it's pretty bad. I think they have one do over try with Facebook though, so it can be corrected easily enough.
Being delinquent with the Nevada SOS (again) is another matter they should work on fixing ASAP, IMO. I don't imagine that looks good to someone doing their DD on FASC.
https://www.facebook.com/MiconexSystems
I am assuming it should say Micronex, and not Miconex?
Merry Christmas to all.
Company Updates
Nov. 27, 2017
Update on Patents Offered for Sale, UTI Presentation at CAOG, and NSF Grant Application
International Patent Offering
NanoLogix is pleased to provide this update on the ongoing work on the sale of the European and China issued FlatPack patents, the poster presentation dealing with the seriousness of the threat from Urinary Tract Infections (UTI) with the need for new rapid methods for diagnostics for UTI infections, and an in-process application to the National Science Foundation for a $1.5 million grant.
Since our first announcement of the offer of 12 July we have registered the patent in fourteen EU Patent Agreement signatory countries. That registration was completed by 7 September. At that time the official status of the FlatPack patent in Europe was recognized in those fourteen countries. Since 7 September, two of those countries, Sweden and Croatia, out of the fourteen countries in which the patent has been registered, have published that information in either their own national patent bulletins or the EU Patent bulletin. This publication step is generally required in order for a formal acceptance of the patent validity by interested parties. NanoLogix has no control over the timing of individual Country publication and hopes the remainder of the bulletin notifications could be completed by the end of the current quarter, fully realizing each country involved possesses its own separate bureaucracy and timetables. That stated, we are pleased to have had interest in the technology from companies in three European and adjacent countries.
For the offering of the FlatPack patent in China we are using the services of a broker in Asia and have as yet to receive notice of significant interest. China and Intellectual property rights have an interesting and varied history so we hope to find a large entity in China with the vision to recognize, acquire, and protect the granted China patent rights.
Central Association of Obstetricians and Gynecologists
Dr. Jonathan Faro, PhD, MD presented the following poster at the CAOG Annual Meeting in Scottsdale, Arizona:
NanoLogix and the authors are in agreement on the need for a rapid definitive diagnostic for UTI and the N-Assay and its soon to be developed screening pre-test are the needed tools to fill the projected need.
National Science Foundation Grant Application
NanoLogix, the Houston medical personnel involved in the N-Assay development and a professional grant writer are finalizing a grant application for $1,500,000.00 from the NSF for funding of both development of a screening ‘pre-test” to be used in conjunction with the N-Assay and also finalization for marketing of the N-Assay. Link to what is offered by the NSF can be found here:
NSF SBIR | NSF SBIR
While there is strong competition for the grants, we believe the N-Assay and what it offers will be attractive to the grant evaluators.
Sept. 1, 2017
Tropical Storm Harvey and FlatPack Update
NanoLogix is donating 1,000 specialized petri plates in 100 FlatPacks of ten plates each to a major hospital in Houston for their use in testing for contamination caused by flooding in their facility. As electrical power loss has been significant in the area a major determining factor in the selection by hospital staff was the ability of our FlatPack petri plates to be stored at room temperature for extended periods, while other manufacturers' products must be refrigerated. This highlights just one of the many qualities of the argon-flushed FlatPack vacuum packaging for petri plates.
The FlatPack, a method of vacuum-packing of petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.
A research paper by a renowned Biomedical Research Center on the qualities of FlatPacked petri plates in a comparison test with competitors can be accessed here:
http://medcraveonline.com/JMEN/JMEN-03-00075.pdf
Aug. 31, 2017
EU, Hong Kong & PRC FlatPack Update
NanoLogix is pleased to announce initial interest from both the EU and PRC areas in the offer for sale of the Flatpack patents for those areas.
To maintain rights for the near future in various EU patent agreement signatory countries while awaiting firm commitments for sale, we are paying the registration fees for the FlatPack patent in the following 14 countries:
Croatia
Denmark
France
Germany
Italy
Ireland
The Netherlands
Poland
Serbia
Spain
Sweden
Switzerland/Lichtenstein
Turkey
The UK
The fees for the 14 countries are approximately $30,000 USD.
The FlatPack, a method of vacuum-packing of petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.
A research paper by a renowned Biomedical Research Center on the qualities of FlatPacked petri plates in a comparison test with competitors can be accessed here:
http://medcraveonline.com/JMEN/JMEN-03-00075.pdf
The decision for patent sale was made based upon the challenges faced in going forward with international development for Nanologix, basically an R&D company for most of its existence with Flatpack Petri sales limited to the US, the UK, and South Africa, versus focusing upon a more easily accessed domestic market and leaving the international market to those large corporations already operating in that environment.
The proceeds from the sales are to be used to expand NanoLogix petri plate production in North America, development of an additional 30+ types of the N-Assay modified ELISA Rapid bacteria detection & identification kits, and other new biotechnology development related to antibody and aptamer use in diagnostics.
Aug. 2, 2017
NanoLogix N-Assay Bacteria Diagnostic Technology To Be Presented Today at AACC Annual Meeting in San Diego
The N-Assay Diagnostic is a novel Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of Deinococcus Bacteria. The following information is being presented today at the American Association for Clinical Chemistry (AACC) 69th Annual Meeting in San Diego:
The significance of the results shown in the presentation cannot be overstated, as with the addition of the Deinococcus results listed, the N-Assay now has demonstrated its applicability across a broad spectrum of bacteria which to date include E.coli, Group B Streptococcus, Enterococcus, and Gonorrhea, in addition to the yeast Candida.
Dr.Jonathan Faro, PhD, MD, tweeted the following two messages yesterday:
"Excited to be at AACC 2017! Over 20,000 registrants and lots of great exhibits!"
"Having a great time at AACC 2017! Getting a lot out of the exhibits. Lots of exciting new technology, but nothing close to the N-Assay!"
You may follow this link to the AACC information website:
https://www.aacc.org/meetings-and-events/2017-annual-meeting
July 12, 2017
NanoLogix Offers EU, Hong Kong & PRC Petri FlatPack Packaging Patents For $35 - $50 Million
HUBBARD, Ohio, July 12, 2017 (GLOBE NEWSWIRE) -- NanoLogix (OTC:NNLX) is pleased to announce the offer for sale of the patents issued in the EU, Hong Kong (Patent EP269949), and the People's Republic of China (PRC Patent CN103842265 (B)) for their unique and exclusively licensed petri plate packaging system known as the FlatPack.
The FlatPack, a method of vacuum-packing for petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.
The FlatPack Patent has been granted in the USA, Mexico, New Zealand, South Africa, the EU (40 Patent signatory countries including Hong Kong), the People's Republic of China, and Chile, and is pending in South Korea, Brazil, and Canada.
The offering price range is cited as the estimate of value for the PRC patent ($35mm) and the EU patent ($15mm). Any interest in patent purchase for the other international granted patents is open for discussion.
A research paper by a renowned Biomedical Research Center on the qualities of FlatPack petri plates in a comparison test with competitors can be accessed here:
http://medcraveonline.com/JMEN/JMEN-03-00075.pdf
The decision for patent sale was made based upon the challenges faced in going forward with international development for NanoLogix, basically an R&D company for most of its existence with FlatPack petri sales limited to the US, the UK, and South Africa, versus focusing upon a more easily accessed domestic market and leaving the international market to those large corporations already operating in that environment.
Sales proceeds will be used for NanoLogix expansion of petri production and sales domestically and development and marketing of their N-Assay Rapid Bacteria Diagnostic Test. The N-Assay provides the most rapid and sensitive diagnostic for bacteria available, coupled with near-simultaneous determination of antibiotic sensitivity.
July 5, 2017
Mexico FlatPack Patent Granted
NanoLogix is extremely pleased to have received notification of grant from the Mexico Patent Office for their unique and exclusively licensed petri plate plate packaging system known as the FlatPack. The FlatPack, a method of vacuum-packing of petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.
This Mexico patent grant follows FlatPack patent grants in the USA, Peoples Republic of China, South Africa, New Zealand, Chile, and the European Union, to include Hong Kong.
A research paper by a renowned Biomedical Research Center on the qualities of FlatPacked petri plates in a comparison test with competitors can be accessed here:
http://medcraveonline.com/JMEN/JMEN-03-00075.pdf
For reference, this patent took nearly 5-1/2 years to be issued from the date of Patent Cooperation Treaty (PCT) filing.
June 22, 2017
EU, Hong Kong & PRC FlatPack Packaging Patents Offered For Sale
NanoLogix is pleased to announce the offer for sale of the patents issued in the EU, Hong Kong, and the Peoples Republic of China for their unique and exclusively licensed petri plate packaging system known as the FlatPack. The FlatPack, a method of vacuum-packing of petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.
A research paper by a renowned Biomedical Research Center on the qualities of FlatPacked petri plates in a comparison test with competitors can be accessed here:
http://medcraveonline.com/JMEN/JMEN-03-00075.pdf
The decision for patent sale was made based upon the challenges faced in going forward with international development for Nanologix, basically an R&D company for most of its existence with Flatpack Petri sales limited to the US, the UK, and South Africa, versus focusing upon a more easily accessed domestic market and leaving the international market to those large corporations already operating in that environment.
The proceeds from the sales are to be used to expand NanoLogix petri plate production in North America, development of an additional 30+ types of the N-Assay modified ELISA Rapid bacteria detection & identification kits, and other new biotechnology development related to antibody and aptamer use in diagnostics.
June 8, 2017
EU & Hong Kong FlatPack Patent Issued
NanoLogix is extremely pleased to announce the patent issuance on 7 June 2017 in the EU and Hong Kong for their unique and exclusively licensed petri plate plate packaging system known as the FlatPack. The FlatPack, a method of vacuum-packing of petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.
A PDF of the issued patent may be viewed here:
http://www.freepatentsonline.com/EP2699491.pdf
A research paper by a renowned Biomedical Research Center on the qualities of FlatPacked petri plates in a comparison test with competitors can be accessed here:
http://medcraveonline.com/JMEN/JMEN-03-00075.pdf
NanoLogix' intention is to register and validate the patent in most of the 40 EU member nations and patent treaty affiliates in addition to Hong Kong. Following that process, NanoLogix intends to seek licencee(s) for manufacturing and marketing for the those areas.
For reference: The patent process from the date of filing to issuance took five years and two months.
June 5, 2017
Reception of the NanoLogix N-Assay Bacteria Diagnostic Technology Poster for E. coli Presented at the American Society for Microbiology (ASM Microbe) Annual meeting
Novel Rapid Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of E. coli O157:H7
Jonathan Faro, MD, PhD and Sebastian Faro, MD, PhD, medical researchers presenting the technology poster at the ASM Annual meeting in New Orleans this past weekend stated:
"ASM Microbe was a very stimulating meeting. We enjoyed meeting many investigators and the engaging discussions that followed. Of the many rapid ID tests either on the market or the many more that presented and will soon be available, our assay is the most unique, and has the ability to provide the greatest limit of detection while simultaneously determining antibiotic susceptibility."
Further information from NanoLogix metrics monitoring indicated interest from at least two major laboratories.
The N-Assay is currently undergoing development for rapid detection of Urinary Tract Infections (UTI) and we anticipate the N-Assay to be debuted soon as the definitive UTI test for speed, accuracy, and sensitivity.
Two published examples of the N-Assay and its performance can be accessed through the following links:
https://www.hindawi.com/journals/idog/2016/5293034/
http://nanologix.com/news/poster-e-coli-0157.pdf
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B
Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
June 2, 2017
Update: NanoLogix N-Assay Bacteria Diagnostic Technology Poster for E. coli To Be Presented Tomorrow at the American Society for Microbiology (ASM) in New Orleans
Novel Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of E. coli O157:H7
This poster presentation will occur Saturday, June 3rd from 12:15 to 14:15 at position #456 in the category of Diagnostic Bacteriology III.
http://nanologix.com/news/poster-e-coli-0157.pdf
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
June 1, 2017
NanoLogix TB Detection Technology Use on Africa Project Increases
NanoLogix is pleased to announce that this week they shipped a new order for their TB Diagnostic test kits for use on an Africa research project funded by the National Institutes of Health, (NIH) the National Institute of Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation, with other funding from US and foreign Government agencies.
This is the third order since April on the Africa Project. NanoLogix was informed that in addition to the two sizes of kits sold in this order (150 mm and 100 mm), NanoLogix should prepare to supply two additional sizes of TB detection kits and also to significantly scale up TB kit production to satisfy projected needs.
For reference from an earlier update: "The technology used in the NanoLogix TB Test Kit is our BNP sandwiched-membrane technology. The use of the TB kit is to provide evidence of the presence of active (live) TB bacteria in a patient sample in 4-6 days rather than 3-5 weeks or more. The results from the NanoLogix TB tests are then processed through PCR (DNA testing) and other means to further define the identity of the TB. The original research paper citing the detection results and potential of pairing the NanoLogix technology with other technologies is available through this link:
https://www.omicsonline.org/1948-5948/JMBT-04-147.digital/JMBT-04-147.html
Related to this work, NanoLogix has received a request to pursue development of an N-Assay modified ELISA for detection and identification of TB. We will be doing so upon receipt of sufficient funding for that goal."
May 19, 2017
NanoLogix N-Assay Bacteria Diagnostic Technology for E. coli limited abstract
Novel Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of E. coli O157:H7
Novel Immunoassay for E coli O157:H7
Researchers: Classified until June 2017
Introduction: E. coli O157:H7 is associated with enterohemorrhagic infections, and is a concern for healthcare providers, food-handlers, and daycare providers. Rapid identification of this pathogen is critical in cases of outbreaks, and empirical treatment with broad-spectrum antibiotics may lead to more severe disease. We have developed an assay that allows for the simultaneous identification of E. coli O157:H7 and determination of its antibiotic susceptibility.
Methods: N-ASSAY
Methods Details Classified until June 2017
Results: O157:H7 was detected at and above 10^6 bacteria/ml following a 30-minute incubation, with no interference by other tested bacteria. By increasing the incubation time to 6 hours, the sensitivity of the test increased to 10^1 bacteria/ml. In addition, incubation with ceftriaxone during this six-hour time period showed inhibition of growth.
Summary: This assay allows for the rapid detection of a high inoculum of E. coli O157:H7, and sensitivity is increased following a six-hour incubation. Importantly, antibiotic susceptibility may be determined during this six-hour incubation.
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
May 8, 2017
Additional TB Test Kits ordered for Third World Gates Foundation Project
NanoLogix is pleased to announce that they have just (8 May 2017) received a new order for double the amount of their TB Diagnostic test kits delivered in April for use on a Third World research project funded by the National Institutes of Health, (NIH) the National Institute of Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation, with other funding from foreign Government agencies.
Since the request from the project representative stated that it is imperative the kits be delivered as soon as possible, NanoLogix is shipping the kits for Wednesday delivery. While the total sales amounts for the TB kits is in the thousands of dollars, Nanologix hopes the sales for use in this and other related TB projects will grow significantly.
The technology used in the NanoLogix TB Test Kit is our BNP sandwiched-membrane technology. The use of the TB kit is to provide evidence of the presence of active (live) TB bacteria in a patient sample in 4-6 days rather than 3-5 weeks or more. The results from the NanoLogix TB tests are then processed through PCR (DNA testing) and other means to further define the identity of the TB. The original research paper citing the detection results and potential of pairing the NanoLogix technology with other technologies is available through this link:
https://www.omicsonline.org/1948-5948/JMBT-04-147.digital/JMBT-04-147.html
Related to this work, NanoLogix has received a request to pursue development of an N-Assay modified ELISA for detection and identification of TB. We will be doing so upon receipt of sufficient funding for that goal.
In other news, patent work on either/both FlatPack and N-Assay patent applications has reached the stage where final examinations have been requested in Mexico, Canada, South Korea, and Brazil. Notification of FlatPack Patent Grant was received last week from Chile.
May 4, 2017
TB test Kits for use in Third World Gates Foundation Project
NanoLogix is pleased to elaborate further on an item of note from last month's announcement regarding shipment of TB Diagnostic kits to a Third World Research Project. The Company has sold and shipped their TB Diagnostic test kits for use on a Third World research project funded by the National Institutes of Health, (NIH) the National Institute of Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation, with other funding from foreign Government agencies.
Three reasons exist for this announcement. The first is to inform the public that whenever we released previous news where we were either named as being associated in research and development by an entity such as the US EPA or the University of Texas Health Science Center in Houston, or were cited in a research paper dealing with our technology by Battelle Biomedical Research Center in Ohio, those entities were all harassed by persons claiming to be NanoLogix shareholders who demanded to know the nature of the business relationships between the entities and NanoLogix and who asked for insider information regarding the status of the ongoing research. Those harassing efforts nearly destroyed the ongoing business relationships NanoLogix was truly privileged to have with those organizations. In this case anyone pursuing the same tact will come up against some very non-receptive forces.
The second is to demonstrate that we at NanoLogix had a goal, and that was to develop and provide to the world, diagnostic and research technologies that are premier and second to none, to create jobs in the rust belt area of northeast Ohio where the mindset of the area is steel mills, auto manufacturing, and low tech service jobs.
The third is to call attention to the facts that we, being a penny stock company, are considered the lowest of the low for investment. We are ignored by brokerages, especially ignored by the local media, and scorned by the investment community in general. Oddly enough, as ignored as we've been, we have still developed customized versions of our new N-Assay modified ELISA rapid bacteria diagnostic for one of the World's largest medical technology companies (under a very strong non-disclosure agreement), worked with the US EPA on developing tests for drinking and source waters, and had our technology presented as the fastest, most accurate and sensitive bacteria diagnostic test in the world. In addition, we've sold large numbers of proprietary packed FlatPacked petri plates in the USA and around the world for use in everything from simple quality control, food processing monitoring, soil testing, cosmetics and personal care products testing, environmental testing for post-flood contamination, water quality analysis, biodefense (we think, but classified), university research, and tens of thousands of users through Amazon and EBay for varied uses.
...and now we've sold TB diagnostics for use on a project funded by whom...?
Our share price and company are under attack by sick manipulators who only hurt dedicated shareholders. We as a company will survive and prosper.
We will expand our facilities as soon as feasible for increased FlatPack and N-Assay production, and are exploring relocating to a different state where we can be considered as bringing a benefit to the area.
Apr. 28, 2017
NanoLogix N-Assay Bacteria Diagnostic Technology for Rare Deinococcus Bacteria to be presented at AACC Annual Meeting in San Diego:
NanoLogix is pleased to announce that the N-Assay Bacteria Diagnostic, recently configured for detection and identification of a rare Deinococcus bacteria species will be presented in poster format at the American Association for Clinical Chemistry (AACC) 69th Annual Scientific Meeting and Clinical Lab Expo, to be held at the San Diego Convention Center in San Diego, California from July 30th through August 3rd, 2017. Dr. Jonathan Faro, MD, PhD and others associated with the development will be present for the poster session.
NanoLogix personnel are exploring the potential of staffing an exhibit booth at the event to display both the new modified-ELISA N-Assay diagnostic kit and also the FlatPack extended shelf life technology for petri plates.
The N-Assay Diagnostic furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus.
The published research results may be accessed through this link:
http://dx.doi.org/10.1155/2016/5293034
The AACC Deinococcus poster presentation illustrates how the N-Assay reduces the detection and identification times from roughly two weeks to a few days, with improved sensitivities over any other known test method.
Further information as to poster display and potential exhibit booth location will be made available in the near future when supplied to us by the AACC. Currently, general information for the event may be found by following this link:
https://www.aacc.org/meetings-and-events/2017-annual-meeting/clinical-lab-expo
The N-Assay Diagnostic for eColi will also be presented at the ASM Microbe 2017 in New Orleans June 1-5. Information for that event is available here:
https://www.asm.org/index.php/asm-microbe-2017
Apr. 4, 2017
NanoLogix has shipped TB test Kits for use in Third World Project
NanoLogix is pleased to announce items of note that have occurred this week. The first is that the Company has sold and shipped their TB Diagnostic test kits for use on a Third World research project funded by multiple US Federal and foreign Government agencies and a large international philanthropic organization. Once the project results are published we will be at liberty to elaborate further. The second item is that the Company today received the largest single delivery to date of petri plates for continued production of prepoured agar-filled FlatPacks, taking delivery of 150,000 sterilized petri plates.
Mar. 16, 2017
NanoLogix N-Assay Bacteria Diagnostic Technology for E. coli to be presented at June ASM Annual Meeting in New Orleans:
NanoLogix is pleased to announce that the N-Assay Bacteria Diagnostic, newly configured for E. coli will be presented in poster format at the American Society for Microbiology ASM Microbe 2017 to be held at the Ernest N. Morial Convention Center in New Orleans, Louisiana from June 1st through 5th. Dr. Sebastian Faro, MD, PhD and others associated with the development will be present for the poster session.
NanoLogix personnel are planning to staff an exhibit booth at the event to display both the Company-offered FlatPack for petri plates and the new N-Assay diagnostic. The FlatPack technology is becoming the premier petri plate storage method for those interested in long life room-temperature storage of prepared agar, with basic poured agars usable in as-new condition after 2-4 years of non-refrigerated storage. The NanoLogix FlatPack is available through www.nanologix.com and also on Amazon.com through two companies --- Evviva Scientific and Diamante Scientific.
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
Further information as to poster display and exhibit booth location will be made available in the near future when supplied to us by the ASM.
Mar. 2, 2017
NanoLogix is pleased to present a further update on the N-Assay Bacteria Diagnostic Technology:
After testing with customized N-Assay kits we supplied in January, the large medical technology client referenced in earlier updates has requested quotes from NanoLogix for expansion and further development using the N-Assay technology to detect additional bacteria species and genera.
Nanologix personnel and associates are excited to work with one of the World's largest medical companies on these N-Assay customizations. Due to a confidentiality agreement with our client, we cannot currently disclose the client identity.
There still remains the step of an independent time and sensitivity study for NanoLogix prior to marketing and sales for clinical use of the N-Assay. Personnel at a number of hospitals are reviewing potential study participation.
Jan. 9, 2017
NanoLogix is pleased to present a brief update on the N-Assay Bacteria Diagnostic Technology:
The N-Assay takes its place on our FDA medical device listing:
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm?lid=469637&lpcd=LIB
There is the remaining step of an independent time and sensitivity study for NanoLogix prior to marketing and sales for clinical use of the N-Assay.
NanoLogix has supplied all of the initially contracted and customized N-Assay kits to our multi-billion dollar medical technology client and we are awaiting results of their global testing.
Dec. 20, 2016
NanoLogix is pleased to announce the following Update:
The Company has narrowed its selection of buildings to use as a larger production facility in northeast Ohio. Two existing buildings are now under consideration to house NanoLogix production for both petri plates and for production of the new N-Assay ELISA-based rapid bacteria diagnostic. The projected expenditure for establishing N-Assay production and increasing petri plate production is roughly $900,000 for production equipment, $125,000 for the construction of two separate 70' X 30' production cleanrooms, and $40,000 for additional equipment such as forklifts.
This expansion is projected to result in market share increase for petri plate sales due to markedly improved economies of scale, and position NanoLogix with a significant production capability for the new N-Assay modified ELISA comprehensive bacteria diagnostic kit. The Company expects the expansion will result in ten additional jobs starting with the delivery and setup of the production equipment in 2017 and another ten positions upon expansion of N-Assay sales.
Over the coming six months we expect to finance the expansion through a combination of increasing revenue from sales of both product lines and fundraising through our current SEC Regulation D, Rule 506 offering for private placement sales of shares.
Any share issuance financing for this expansion is being structured primarily, but not solely, through a series of equity tranches and stock warrants. Using this method, the Company hopes to keep stock dilution to a minimum and will proceed with the interests of the shareholders in mind, including extending the timeline for expansion as necessary if equity costs are not favorable to NanoLogix.
The Company is preparing to seek licensees in Europe and Hong Kong for production of FlatPack Petri Plates under the recent EU FlatPack patent approval.
In response to queries coming to our office regarding our customization of the N-Assay for a multibillion medical technology company: we have sold 600+ of the N-Assay to them and will be supplying more in addition to further customization for other bacteria in 2017. As our arrangement with the client is CONFIDENTIAL, we will not be releasing their name.
Merry Christmas from Carol, Debby, Kim, Travis, Bret and all
Dec. 6, 2016
NanoLogix is pleased to announce the following Update:
The Company is currently searching for a larger production facility in northeast Ohio. In the past three weeks NanoLogix management and production staff have viewed, toured, and measured four separate sites to ascertain site suitability for relocating and expanding NanoLogix production for both petri plates and for production of the new N-Assay ELISA-based rapid bacteria diagnostic.
The new sites being surveyed range from 10,000 square feet to 22,000 square feet, three to seven times the size of our current facility. All sites viewed offer additional square footage for further expansion as required.
NanoLogix is also in the process of specifying and ordering new equipment for the production of both petri plates and the new N-Assay.
The two petri plate filling machines that have been configured for order are both OnlineEngineering MultiDish Model 968 with ancillary equipment. The Model 968 is capable of filling 9,600 plates per hour, so the two machines should be capable of meeting production needs for the forseeable future. Further information on the equipment can be found at: www.online-engineering.com
The N-Assay equipment currently being researched and specified are automatic pippetting machines for application of antibodies, etc., to the ELISA plates used for this revolutionary rapid bacteria diagnostic technology.
The two technologies will be housed in separate modular cleanrooms in order to comply with specific FDA requirements for manufacturing of each product.
The projected timeline for delivery and assembly of modular cleanrooms, the OnlineEngineering equipment, and the automated pippetting machines is sometime in the second quarter of 2017, while configuration of whichever of the candidate sites is chosen is projected to begin in the first quarter of 2017.
Petri plate production is currently in Hubbard, Ohio, while N-Assay production is in Houston, Texas. N-Assay production in Ohio is projected to begin in the second quarter of 2017.
------------------------------------------------------------------------------------------------------------------------------
Updates are available by signing up for eNews on the company's homepage at nanologix.com.
The sheer laziness of it all:
https://micronexsystems.com/applications/biofuels/
Empty Fruit Bunches (EFB or Palm Waste)
In Asia, large quantities of palm waste also called Empty Fruit Bunches or EFB are available from plantations where palm oil is produced. In its raw state, EFB is both very fibrous and wet. If it could be dried, it would be an excellent fuel for power boilers. FASC Malaysia has installed a KDS machine in the 14 MWe TSH Biomass Power Plant in Kunak, Malaysia, for the purpose of drying EFB. Called the KDS MF-777, it dries and shreds EFB so that it can be burned as a fuel. At present, only one-sixth of the fuel input needed by the TSH power plant is supplied by the KDS MF-777. The KDS MF-777 processes 3750 kg/hr of raw EFB having a moisture content of 52 % and produces 3000 kg/hr of shredded EFB which has a moisture content of 40 % – this is dry enough for burning on a grate. The power consumption of the MF-777 is only 200 kW, under these operating conditions. This translates to a drying energy consumption of only 960 kJ per kg of water removal (= 414 BTU/lb) or only 44 % of the latent heat of water! No other dryer technology can match the low energy consumption of the KDS MF-777. It is well-known among power plant engineers that every percentage point of moisture in the fuel causes 0.5-1 % reduction in the electricity produced. Thus, the estimated maximum possible increase in the TSH power plant output because of drying the fuel in the KDS MF-777 is 0.84-1.68 MWe. Thus, a net overall increase in the total power generated becomes possible due to the KDS MF-777. Therefore, the cost of the KDS equipment can be recouped from the extra revenue from the increased electricity production.
Company Updates
Sept. 1, 2017
Tropical Storm Harvey and FlatPack Update
NanoLogix is donating 1,000 specialized petri plates in 100 FlatPacks of ten plates each to a major hospital in Houston for their use in testing for contamination caused by flooding in their facility. As electrical power loss has been significant in the area a major determining factor in the selection by hospital staff was the ability of our FlatPack petri plates to be stored at room temperature for extended periods, while other manufacturers' products must be refrigerated. This highlights just one of the many qualities of the argon-flushed FlatPack vacuum packaging for petri plates.
The FlatPack, a method of vacuum-packing of petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.
A research paper by a renowned Biomedical Research Center on the qualities of FlatPacked petri plates in a comparison test with competitors can be accessed here:
http://medcraveonline.com/JMEN/JMEN-03-00075.pdf
Aug. 31, 2017
EU, Hong Kong & PRC FlatPack Update
NanoLogix is pleased to announce initial interest from both the EU and PRC areas in the offer for sale of the Flatpack patents for those areas.
To maintain rights for the near future in various EU patent agreement signatory countries while awaiting firm commitments for sale, we are paying the registration fees for the FlatPack patent in the following 14 countries:
Croatia
Denmark
France
Germany
Italy
Ireland
The Netherlands
Poland
Serbia
Spain
Sweden
Switzerland/Lichtenstein
Turkey
The UK
The fees for the 14 countries are approximately $30,000 USD.
The FlatPack, a method of vacuum-packing of petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.
A research paper by a renowned Biomedical Research Center on the qualities of FlatPacked petri plates in a comparison test with competitors can be accessed here:
http://medcraveonline.com/JMEN/JMEN-03-00075.pdf
The decision for patent sale was made based upon the challenges faced in going forward with international development for Nanologix, basically an R&D company for most of its existence with Flatpack Petri sales limited to the US, the UK, and South Africa, versus focusing upon a more easily accessed domestic market and leaving the international market to those large corporations already operating in that environment.
The proceeds from the sales are to be used to expand NanoLogix petri plate production in North America, development of an additional 30+ types of the N-Assay modified ELISA Rapid bacteria detection & identification kits, and other new biotechnology development related to antibody and aptamer use in diagnostics.
Aug. 2, 2017
NanoLogix N-Assay Bacteria Diagnostic Technology To Be Presented Today at AACC Annual Meeting in San Diego
The N-Assay Diagnostic is a novel Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of Deinococcus Bacteria. The following information is being presented today at the American Association for Clinical Chemistry (AACC) 69th Annual Meeting in San Diego:
The significance of the results shown in the presentation cannot be overstated, as with the addition of the Deinococcus results listed, the N-Assay now has demonstrated its applicability across a broad spectrum of bacteria which to date include E.coli, Group B Streptococcus, Enterococcus, and Gonorrhea, in addition to the yeast Candida.
Dr.Jonathan Faro, PhD, MD, tweeted the following two messages yesterday:
"Excited to be at AACC 2017! Over 20,000 registrants and lots of great exhibits!"
"Having a great time at AACC 2017! Getting a lot out of the exhibits. Lots of exciting new technology, but nothing close to the N-Assay!"
You may follow this link to the AACC information website:
https://www.aacc.org/meetings-and-events/2017-annual-meeting
July 12, 2017
NanoLogix Offers EU, Hong Kong & PRC Petri FlatPack Packaging Patents For $35 - $50 Million
HUBBARD, Ohio, July 12, 2017 (GLOBE NEWSWIRE) -- NanoLogix (OTC:NNLX) is pleased to announce the offer for sale of the patents issued in the EU, Hong Kong (Patent EP269949), and the People's Republic of China (PRC Patent CN103842265 (B)) for their unique and exclusively licensed petri plate packaging system known as the FlatPack.
The FlatPack, a method of vacuum-packing for petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.
The FlatPack Patent has been granted in the USA, Mexico, New Zealand, South Africa, the EU (40 Patent signatory countries including Hong Kong), the People's Republic of China, and Chile, and is pending in South Korea, Brazil, and Canada.
The offering price range is cited as the estimate of value for the PRC patent ($35mm) and the EU patent ($15mm). Any interest in patent purchase for the other international granted patents is open for discussion.
A research paper by a renowned Biomedical Research Center on the qualities of FlatPack petri plates in a comparison test with competitors can be accessed here:
http://medcraveonline.com/JMEN/JMEN-03-00075.pdf
The decision for patent sale was made based upon the challenges faced in going forward with international development for NanoLogix, basically an R&D company for most of its existence with FlatPack petri sales limited to the US, the UK, and South Africa, versus focusing upon a more easily accessed domestic market and leaving the international market to those large corporations already operating in that environment.
Sales proceeds will be used for NanoLogix expansion of petri production and sales domestically and development and marketing of their N-Assay Rapid Bacteria Diagnostic Test. The N-Assay provides the most rapid and sensitive diagnostic for bacteria available, coupled with near-simultaneous determination of antibiotic sensitivity.
July 5, 2017
Mexico FlatPack Patent Granted
NanoLogix is extremely pleased to have received notification of grant from the Mexico Patent Office for their unique and exclusively licensed petri plate plate packaging system known as the FlatPack. The FlatPack, a method of vacuum-packing of petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.
This Mexico patent grant follows FlatPack patent grants in the USA, Peoples Republic of China, South Africa, New Zealand, Chile, and the European Union, to include Hong Kong.
A research paper by a renowned Biomedical Research Center on the qualities of FlatPacked petri plates in a comparison test with competitors can be accessed here:
http://medcraveonline.com/JMEN/JMEN-03-00075.pdf
For reference, this patent took nearly 5-1/2 years to be issued from the date of Patent Cooperation Treaty (PCT) filing.
June 22, 2017
EU, Hong Kong & PRC FlatPack Packaging Patents Offered For Sale
NanoLogix is pleased to announce the offer for sale of the patents issued in the EU, Hong Kong, and the Peoples Republic of China for their unique and exclusively licensed petri plate packaging system known as the FlatPack. The FlatPack, a method of vacuum-packing of petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.
A research paper by a renowned Biomedical Research Center on the qualities of FlatPacked petri plates in a comparison test with competitors can be accessed here:
http://medcraveonline.com/JMEN/JMEN-03-00075.pdf
The decision for patent sale was made based upon the challenges faced in going forward with international development for Nanologix, basically an R&D company for most of its existence with Flatpack Petri sales limited to the US, the UK, and South Africa, versus focusing upon a more easily accessed domestic market and leaving the international market to those large corporations already operating in that environment.
The proceeds from the sales are to be used to expand NanoLogix petri plate production in North America, development of an additional 30+ types of the N-Assay modified ELISA Rapid bacteria detection & identification kits, and other new biotechnology development related to antibody and aptamer use in diagnostics.
June 8, 2017
EU & Hong Kong FlatPack Patent Issued
NanoLogix is extremely pleased to announce the patent issuance on 7 June 2017 in the EU and Hong Kong for their unique and exclusively licensed petri plate plate packaging system known as the FlatPack. The FlatPack, a method of vacuum-packing of petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.
A PDF of the issued patent may be viewed here:
http://www.freepatentsonline.com/EP2699491.pdf
A research paper by a renowned Biomedical Research Center on the qualities of FlatPacked petri plates in a comparison test with competitors can be accessed here:
http://medcraveonline.com/JMEN/JMEN-03-00075.pdf
NanoLogix' intention is to register and validate the patent in most of the 40 EU member nations and patent treaty affiliates in addition to Hong Kong. Following that process, NanoLogix intends to seek licencee(s) for manufacturing and marketing for the those areas.
For reference: The patent process from the date of filing to issuance took five years and two months.
June 5, 2017
Reception of the NanoLogix N-Assay Bacteria Diagnostic Technology Poster for E. coli Presented at the American Society for Microbiology (ASM Microbe) Annual meeting
Novel Rapid Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of E. coli O157:H7
Jonathan Faro, MD, PhD and Sebastian Faro, MD, PhD, medical researchers presenting the technology poster at the ASM Annual meeting in New Orleans this past weekend stated:
"ASM Microbe was a very stimulating meeting. We enjoyed meeting many investigators and the engaging discussions that followed. Of the many rapid ID tests either on the market or the many more that presented and will soon be available, our assay is the most unique, and has the ability to provide the greatest limit of detection while simultaneously determining antibiotic susceptibility."
Further information from NanoLogix metrics monitoring indicated interest from at least two major laboratories.
The N-Assay is currently undergoing development for rapid detection of Urinary Tract Infections (UTI) and we anticipate the N-Assay to be debuted soon as the definitive UTI test for speed, accuracy, and sensitivity.
Two published examples of the N-Assay and its performance can be accessed through the following links:
https://www.hindawi.com/journals/idog/2016/5293034/
http://nanologix.com/news/poster-e-coli-0157.pdf
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B
Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
June 2, 2017
Update: NanoLogix N-Assay Bacteria Diagnostic Technology Poster for E. coli To Be Presented Tomorrow at the American Society for Microbiology (ASM) in New Orleans
Novel Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of E. coli O157:H7
This poster presentation will occur Saturday, June 3rd from 12:15 to 14:15 at position #456 in the category of Diagnostic Bacteriology III.
http://nanologix.com/news/poster-e-coli-0157.pdf
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
June 1, 2017
NanoLogix TB Detection Technology Use on Africa Project Increases
NanoLogix is pleased to announce that this week they shipped a new order for their TB Diagnostic test kits for use on an Africa research project funded by the National Institutes of Health, (NIH) the National Institute of Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation, with other funding from US and foreign Government agencies.
This is the third order since April on the Africa Project. NanoLogix was informed that in addition to the two sizes of kits sold in this order (150 mm and 100 mm), NanoLogix should prepare to supply two additional sizes of TB detection kits and also to significantly scale up TB kit production to satisfy projected needs.
For reference from an earlier update: "The technology used in the NanoLogix TB Test Kit is our BNP sandwiched-membrane technology. The use of the TB kit is to provide evidence of the presence of active (live) TB bacteria in a patient sample in 4-6 days rather than 3-5 weeks or more. The results from the NanoLogix TB tests are then processed through PCR (DNA testing) and other means to further define the identity of the TB. The original research paper citing the detection results and potential of pairing the NanoLogix technology with other technologies is available through this link:
https://www.omicsonline.org/1948-5948/JMBT-04-147.digital/JMBT-04-147.html
Related to this work, NanoLogix has received a request to pursue development of an N-Assay modified ELISA for detection and identification of TB. We will be doing so upon receipt of sufficient funding for that goal."
May 19, 2017
NanoLogix N-Assay Bacteria Diagnostic Technology for E. coli limited abstract
Novel Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of E. coli O157:H7
Novel Immunoassay for E coli O157:H7
Researchers: Classified until June 2017
Introduction: E. coli O157:H7 is associated with enterohemorrhagic infections, and is a concern for healthcare providers, food-handlers, and daycare providers. Rapid identification of this pathogen is critical in cases of outbreaks, and empirical treatment with broad-spectrum antibiotics may lead to more severe disease. We have developed an assay that allows for the simultaneous identification of E. coli O157:H7 and determination of its antibiotic susceptibility.
Methods: N-ASSAY
Methods Details Classified until June 2017
Results: O157:H7 was detected at and above 10^6 bacteria/ml following a 30-minute incubation, with no interference by other tested bacteria. By increasing the incubation time to 6 hours, the sensitivity of the test increased to 10^1 bacteria/ml. In addition, incubation with ceftriaxone during this six-hour time period showed inhibition of growth.
Summary: This assay allows for the rapid detection of a high inoculum of E. coli O157:H7, and sensitivity is increased following a six-hour incubation. Importantly, antibiotic susceptibility may be determined during this six-hour incubation.
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
May 8, 2017
Additional TB Test Kits ordered for Third World Gates Foundation Project
NanoLogix is pleased to announce that they have just (8 May 2017) received a new order for double the amount of their TB Diagnostic test kits delivered in April for use on a Third World research project funded by the National Institutes of Health, (NIH) the National Institute of Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation, with other funding from foreign Government agencies.
Since the request from the project representative stated that it is imperative the kits be delivered as soon as possible, NanoLogix is shipping the kits for Wednesday delivery. While the total sales amounts for the TB kits is in the thousands of dollars, Nanologix hopes the sales for use in this and other related TB projects will grow significantly.
The technology used in the NanoLogix TB Test Kit is our BNP sandwiched-membrane technology. The use of the TB kit is to provide evidence of the presence of active (live) TB bacteria in a patient sample in 4-6 days rather than 3-5 weeks or more. The results from the NanoLogix TB tests are then processed through PCR (DNA testing) and other means to further define the identity of the TB. The original research paper citing the detection results and potential of pairing the NanoLogix technology with other technologies is available through this link:
https://www.omicsonline.org/1948-5948/JMBT-04-147.digital/JMBT-04-147.html
Related to this work, NanoLogix has received a request to pursue development of an N-Assay modified ELISA for detection and identification of TB. We will be doing so upon receipt of sufficient funding for that goal.
In other news, patent work on either/both FlatPack and N-Assay patent applications has reached the stage where final examinations have been requested in Mexico, Canada, South Korea, and Brazil. Notification of FlatPack Patent Grant was received last week from Chile.
May 4, 2017
TB test Kits for use in Third World Gates Foundation Project
NanoLogix is pleased to elaborate further on an item of note from last month's announcement regarding shipment of TB Diagnostic kits to a Third World Research Project. The Company has sold and shipped their TB Diagnostic test kits for use on a Third World research project funded by the National Institutes of Health, (NIH) the National Institute of Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation, with other funding from foreign Government agencies.
Three reasons exist for this announcement. The first is to inform the public that whenever we released previous news where we were either named as being associated in research and development by an entity such as the US EPA or the University of Texas Health Science Center in Houston, or were cited in a research paper dealing with our technology by Battelle Biomedical Research Center in Ohio, those entities were all harassed by persons claiming to be NanoLogix shareholders who demanded to know the nature of the business relationships between the entities and NanoLogix and who asked for insider information regarding the status of the ongoing research. Those harassing efforts nearly destroyed the ongoing business relationships NanoLogix was truly privileged to have with those organizations. In this case anyone pursuing the same tact will come up against some very non-receptive forces.
The second is to demonstrate that we at NanoLogix had a goal, and that was to develop and provide to the world, diagnostic and research technologies that are premier and second to none, to create jobs in the rust belt area of northeast Ohio where the mindset of the area is steel mills, auto manufacturing, and low tech service jobs.
The third is to call attention to the facts that we, being a penny stock company, are considered the lowest of the low for investment. We are ignored by brokerages, especially ignored by the local media, and scorned by the investment community in general. Oddly enough, as ignored as we've been, we have still developed customized versions of our new N-Assay modified ELISA rapid bacteria diagnostic for one of the World's largest medical technology companies (under a very strong non-disclosure agreement), worked with the US EPA on developing tests for drinking and source waters, and had our technology presented as the fastest, most accurate and sensitive bacteria diagnostic test in the world. In addition, we've sold large numbers of proprietary packed FlatPacked petri plates in the USA and around the world for use in everything from simple quality control, food processing monitoring, soil testing, cosmetics and personal care products testing, environmental testing for post-flood contamination, water quality analysis, biodefense (we think, but classified), university research, and tens of thousands of users through Amazon and EBay for varied uses.
...and now we've sold TB diagnostics for use on a project funded by whom...?
Our share price and company are under attack by sick manipulators who only hurt dedicated shareholders. We as a company will survive and prosper.
We will expand our facilities as soon as feasible for increased FlatPack and N-Assay production, and are exploring relocating to a different state where we can be considered as bringing a benefit to the area.
Apr. 28, 2017
NanoLogix N-Assay Bacteria Diagnostic Technology for Rare Deinococcus Bacteria to be presented at AACC Annual Meeting in San Diego:
NanoLogix is pleased to announce that the N-Assay Bacteria Diagnostic, recently configured for detection and identification of a rare Deinococcus bacteria species will be presented in poster format at the American Association for Clinical Chemistry (AACC) 69th Annual Scientific Meeting and Clinical Lab Expo, to be held at the San Diego Convention Center in San Diego, California from July 30th through August 3rd, 2017. Dr. Jonathan Faro, MD, PhD and others associated with the development will be present for the poster session.
NanoLogix personnel are exploring the potential of staffing an exhibit booth at the event to display both the new modified-ELISA N-Assay diagnostic kit and also the FlatPack extended shelf life technology for petri plates.
The N-Assay Diagnostic furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus.
The published research results may be accessed through this link:
http://dx.doi.org/10.1155/2016/5293034
The AACC Deinococcus poster presentation illustrates how the N-Assay reduces the detection and identification times from roughly two weeks to a few days, with improved sensitivities over any other known test method.
Further information as to poster display and potential exhibit booth location will be made available in the near future when supplied to us by the AACC. Currently, general information for the event may be found by following this link:
https://www.aacc.org/meetings-and-events/2017-annual-meeting/clinical-lab-expo
The N-Assay Diagnostic for eColi will also be presented at the ASM Microbe 2017 in New Orleans June 1-5. Information for that event is available here:
https://www.asm.org/index.php/asm-microbe-2017
Apr. 4, 2017
NanoLogix has shipped TB test Kits for use in Third World Project
NanoLogix is pleased to announce items of note that have occurred this week. The first is that the Company has sold and shipped their TB Diagnostic test kits for use on a Third World research project funded by multiple US Federal and foreign Government agencies and a large international philanthropic organization. Once the project results are published we will be at liberty to elaborate further. The second item is that the Company today received the largest single delivery to date of petri plates for continued production of prepoured agar-filled FlatPacks, taking delivery of 150,000 sterilized petri plates.
Mar. 16, 2017
NanoLogix N-Assay Bacteria Diagnostic Technology for E. coli to be presented at June ASM Annual Meeting in New Orleans:
NanoLogix is pleased to announce that the N-Assay Bacteria Diagnostic, newly configured for E. coli will be presented in poster format at the American Society for Microbiology ASM Microbe 2017 to be held at the Ernest N. Morial Convention Center in New Orleans, Louisiana from June 1st through 5th. Dr. Sebastian Faro, MD, PhD and others associated with the development will be present for the poster session.
NanoLogix personnel are planning to staff an exhibit booth at the event to display both the Company-offered FlatPack for petri plates and the new N-Assay diagnostic. The FlatPack technology is becoming the premier petri plate storage method for those interested in long life room-temperature storage of prepared agar, with basic poured agars usable in as-new condition after 2-4 years of non-refrigerated storage. The NanoLogix FlatPack is available through www.nanologix.com and also on Amazon.com through two companies --- Evviva Scientific and Diamante Scientific.
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
Further information as to poster display and exhibit booth location will be made available in the near future when supplied to us by the ASM.
Mar. 2, 2017
NanoLogix is pleased to present a further update on the N-Assay Bacteria Diagnostic Technology:
After testing with customized N-Assay kits we supplied in January, the large medical technology client referenced in earlier updates has requested quotes from NanoLogix for expansion and further development using the N-Assay technology to detect additional bacteria species and genera.
Nanologix personnel and associates are excited to work with one of the World's largest medical companies on these N-Assay customizations. Due to a confidentiality agreement with our client, we cannot currently disclose the client identity.
There still remains the step of an independent time and sensitivity study for NanoLogix prior to marketing and sales for clinical use of the N-Assay. Personnel at a number of hospitals are reviewing potential study participation.
Jan. 9, 2017
NanoLogix is pleased to present a brief update on the N-Assay Bacteria Diagnostic Technology:
The N-Assay takes its place on our FDA medical device listing:
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm?lid=469637&lpcd=LIB
There is the remaining step of an independent time and sensitivity study for NanoLogix prior to marketing and sales for clinical use of the N-Assay.
NanoLogix has supplied all of the initially contracted and customized N-Assay kits to our multi-billion dollar medical technology client and we are awaiting results of their global testing.
Dec. 20, 2016
NanoLogix is pleased to announce the following Update:
The Company has narrowed its selection of buildings to use as a larger production facility in northeast Ohio. Two existing buildings are now under consideration to house NanoLogix production for both petri plates and for production of the new N-Assay ELISA-based rapid bacteria diagnostic. The projected expenditure for establishing N-Assay production and increasing petri plate production is roughly $900,000 for production equipment, $125,000 for the construction of two separate 70' X 30' production cleanrooms, and $40,000 for additional equipment such as forklifts.
This expansion is projected to result in market share increase for petri plate sales due to markedly improved economies of scale, and position NanoLogix with a significant production capability for the new N-Assay modified ELISA comprehensive bacteria diagnostic kit. The Company expects the expansion will result in ten additional jobs starting with the delivery and setup of the production equipment in 2017 and another ten positions upon expansion of N-Assay sales.
Over the coming six months we expect to finance the expansion through a combination of increasing revenue from sales of both product lines and fundraising through our current SEC Regulation D, Rule 506 offering for private placement sales of shares.
Any share issuance financing for this expansion is being structured primarily, but not solely, through a series of equity tranches and stock warrants. Using this method, the Company hopes to keep stock dilution to a minimum and will proceed with the interests of the shareholders in mind, including extending the timeline for expansion as necessary if equity costs are not favorable to NanoLogix.
The Company is preparing to seek licensees in Europe and Hong Kong for production of FlatPack Petri Plates under the recent EU FlatPack patent approval.
In response to queries coming to our office regarding our customization of the N-Assay for a multibillion medical technology company: we have sold 600+ of the N-Assay to them and will be supplying more in addition to further customization for other bacteria in 2017. As our arrangement with the client is CONFIDENTIAL, we will not be releasing their name.
Merry Christmas from Carol, Debby, Kim, Travis, Bret and all
Dec. 6, 2016
NanoLogix is pleased to announce the following Update:
The Company is currently searching for a larger production facility in northeast Ohio. In the past three weeks NanoLogix management and production staff have viewed, toured, and measured four separate sites to ascertain site suitability for relocating and expanding NanoLogix production for both petri plates and for production of the new N-Assay ELISA-based rapid bacteria diagnostic.
The new sites being surveyed range from 10,000 square feet to 22,000 square feet, three to seven times the size of our current facility. All sites viewed offer additional square footage for further expansion as required.
NanoLogix is also in the process of specifying and ordering new equipment for the production of both petri plates and the new N-Assay.
The two petri plate filling machines that have been configured for order are both OnlineEngineering MultiDish Model 968 with ancillary equipment. The Model 968 is capable of filling 9,600 plates per hour, so the two machines should be capable of meeting production needs for the forseeable future. Further information on the equipment can be found at: www.online-engineering.com
The N-Assay equipment currently being researched and specified are automatic pippetting machines for application of antibodies, etc., to the ELISA plates used for this revolutionary rapid bacteria diagnostic technology.
The two technologies will be housed in separate modular cleanrooms in order to comply with specific FDA requirements for manufacturing of each product.
The projected timeline for delivery and assembly of modular cleanrooms, the OnlineEngineering equipment, and the automated pippetting machines is sometime in the second quarter of 2017, while configuration of whichever of the candidate sites is chosen is projected to begin in the first quarter of 2017.
Petri plate production is currently in Hubbard, Ohio, while N-Assay production is in Houston, Texas. N-Assay production in Ohio is projected to begin in the second quarter of 2017.
------------------------------------------------------------------------------------------------------------------------------
Updates are available by signing up for eNews on the company's homepage at nanologix.com.
Company Updates
Aug. 2, 2017
NanoLogix N-Assay Bacteria Diagnostic Technology To Be Presented Today at AACC Annual Meeting in San Diego
The N-Assay Diagnostic is a novel Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of Deinococcus Bacteria. The following information is being presented today at the American Association for Clinical Chemistry (AACC) 69th Annual Meeting in San Diego:
The significance of the results shown in the presentation cannot be overstated, as with the addition of the Deinococcus results listed, the N-Assay now has demonstrated its applicability across a broad spectrum of bacteria which to date include E.coli, Group B Streptococcus, Enterococcus, and Gonorrhea, in addition to the yeast Candida.
Dr.Jonathan Faro, PhD, MD, tweeted the following two messages yesterday:
"Excited to be at AACC 2017! Over 20,000 registrants and lots of great exhibits!"
"Having a great time at AACC 2017! Getting a lot out of the exhibits. Lots of exciting new technology, but nothing close to the N-Assay!"
You may follow this link to the AACC information website:
https://www.aacc.org/meetings-and-events/2017-annual-meeting
July 12, 2017
NanoLogix Offers EU, Hong Kong & PRC Petri FlatPack Packaging Patents For $35 - $50 Million
HUBBARD, Ohio, July 12, 2017 (GLOBE NEWSWIRE) -- NanoLogix (OTC:NNLX) is pleased to announce the offer for sale of the patents issued in the EU, Hong Kong (Patent EP269949), and the People's Republic of China (PRC Patent CN103842265 (B)) for their unique and exclusively licensed petri plate packaging system known as the FlatPack.
The FlatPack, a method of vacuum-packing for petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.
The FlatPack Patent has been granted in the USA, Mexico, New Zealand, South Africa, the EU (40 Patent signatory countries including Hong Kong), the People's Republic of China, and Chile, and is pending in South Korea, Brazil, and Canada.
The offering price range is cited as the estimate of value for the PRC patent ($35mm) and the EU patent ($15mm). Any interest in patent purchase for the other international granted patents is open for discussion.
A research paper by a renowned Biomedical Research Center on the qualities of FlatPack petri plates in a comparison test with competitors can be accessed here:
http://medcraveonline.com/JMEN/JMEN-03-00075.pdf
The decision for patent sale was made based upon the challenges faced in going forward with international development for NanoLogix, basically an R&D company for most of its existence with FlatPack petri sales limited to the US, the UK, and South Africa, versus focusing upon a more easily accessed domestic market and leaving the international market to those large corporations already operating in that environment.
Sales proceeds will be used for NanoLogix expansion of petri production and sales domestically and development and marketing of their N-Assay Rapid Bacteria Diagnostic Test. The N-Assay provides the most rapid and sensitive diagnostic for bacteria available, coupled with near-simultaneous determination of antibiotic sensitivity.
July 5, 2017
Mexico FlatPack Patent Granted
NanoLogix is extremely pleased to have received notification of grant from the Mexico Patent Office for their unique and exclusively licensed petri plate plate packaging system known as the FlatPack. The FlatPack, a method of vacuum-packing of petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.
This Mexico patent grant follows FlatPack patent grants in the USA, Peoples Republic of China, South Africa, New Zealand, Chile, and the European Union, to include Hong Kong.
A research paper by a renowned Biomedical Research Center on the qualities of FlatPacked petri plates in a comparison test with competitors can be accessed here:
http://medcraveonline.com/JMEN/JMEN-03-00075.pdf
For reference, this patent took nearly 5-1/2 years to be issued from the date of Patent Cooperation Treaty (PCT) filing.
June 22, 2017
EU, Hong Kong & PRC FlatPack Packaging Patents Offered For Sale
NanoLogix is pleased to announce the offer for sale of the patents issued in the EU, Hong Kong, and the Peoples Republic of China for their unique and exclusively licensed petri plate packaging system known as the FlatPack. The FlatPack, a method of vacuum-packing of petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.
A research paper by a renowned Biomedical Research Center on the qualities of FlatPacked petri plates in a comparison test with competitors can be accessed here:
http://medcraveonline.com/JMEN/JMEN-03-00075.pdf
The decision for patent sale was made based upon the challenges faced in going forward with international development for Nanologix, basically an R&D company for most of its existence with Flatpack Petri sales limited to the US, the UK, and South Africa, versus focusing upon a more easily accessed domestic market and leaving the international market to those large corporations already operating in that environment.
The proceeds from the sales are to be used to expand NanoLogix petri plate production in North America, development of an additional 30+ types of the N-Assay modified ELISA Rapid bacteria detection & identification kits, and other new biotechnology development related to antibody and aptamer use in diagnostics.
June 8, 2017
EU & Hong Kong FlatPack Patent Issued
NanoLogix is extremely pleased to announce the patent issuance on 7 June 2017 in the EU and Hong Kong for their unique and exclusively licensed petri plate plate packaging system known as the FlatPack. The FlatPack, a method of vacuum-packing of petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.
A PDF of the issued patent may be viewed here:
http://www.freepatentsonline.com/EP2699491.pdf
A research paper by a renowned Biomedical Research Center on the qualities of FlatPacked petri plates in a comparison test with competitors can be accessed here:
http://medcraveonline.com/JMEN/JMEN-03-00075.pdf
NanoLogix' intention is to register and validate the patent in most of the 40 EU member nations and patent treaty affiliates in addition to Hong Kong. Following that process, NanoLogix intends to seek licencee(s) for manufacturing and marketing for the those areas.
For reference: The patent process from the date of filing to issuance took five years and two months.
June 5, 2017
Reception of the NanoLogix N-Assay Bacteria Diagnostic Technology Poster for E. coli Presented at the American Society for Microbiology (ASM Microbe) Annual meeting
Novel Rapid Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of E. coli O157:H7
Jonathan Faro, MD, PhD and Sebastian Faro, MD, PhD, medical researchers presenting the technology poster at the ASM Annual meeting in New Orleans this past weekend stated:
"ASM Microbe was a very stimulating meeting. We enjoyed meeting many investigators and the engaging discussions that followed. Of the many rapid ID tests either on the market or the many more that presented and will soon be available, our assay is the most unique, and has the ability to provide the greatest limit of detection while simultaneously determining antibiotic susceptibility."
Further information from NanoLogix metrics monitoring indicated interest from at least two major laboratories.
The N-Assay is currently undergoing development for rapid detection of Urinary Tract Infections (UTI) and we anticipate the N-Assay to be debuted soon as the definitive UTI test for speed, accuracy, and sensitivity.
Two published examples of the N-Assay and its performance can be accessed through the following links:
https://www.hindawi.com/journals/idog/2016/5293034/
http://nanologix.com/news/poster-e-coli-0157.pdf
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B
Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
June 2, 2017
Update: NanoLogix N-Assay Bacteria Diagnostic Technology Poster for E. coli To Be Presented Tomorrow at the American Society for Microbiology (ASM) in New Orleans
Novel Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of E. coli O157:H7
This poster presentation will occur Saturday, June 3rd from 12:15 to 14:15 at position #456 in the category of Diagnostic Bacteriology III.
http://nanologix.com/news/poster-e-coli-0157.pdf
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
June 1, 2017
NanoLogix TB Detection Technology Use on Africa Project Increases
NanoLogix is pleased to announce that this week they shipped a new order for their TB Diagnostic test kits for use on an Africa research project funded by the National Institutes of Health, (NIH) the National Institute of Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation, with other funding from US and foreign Government agencies.
This is the third order since April on the Africa Project. NanoLogix was informed that in addition to the two sizes of kits sold in this order (150 mm and 100 mm), NanoLogix should prepare to supply two additional sizes of TB detection kits and also to significantly scale up TB kit production to satisfy projected needs.
For reference from an earlier update: "The technology used in the NanoLogix TB Test Kit is our BNP sandwiched-membrane technology. The use of the TB kit is to provide evidence of the presence of active (live) TB bacteria in a patient sample in 4-6 days rather than 3-5 weeks or more. The results from the NanoLogix TB tests are then processed through PCR (DNA testing) and other means to further define the identity of the TB. The original research paper citing the detection results and potential of pairing the NanoLogix technology with other technologies is available through this link:
https://www.omicsonline.org/1948-5948/JMBT-04-147.digital/JMBT-04-147.html
Related to this work, NanoLogix has received a request to pursue development of an N-Assay modified ELISA for detection and identification of TB. We will be doing so upon receipt of sufficient funding for that goal."
May 19, 2017
NanoLogix N-Assay Bacteria Diagnostic Technology for E. coli limited abstract
Novel Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of E. coli O157:H7
Novel Immunoassay for E coli O157:H7
Researchers: Classified until June 2017
Introduction: E. coli O157:H7 is associated with enterohemorrhagic infections, and is a concern for healthcare providers, food-handlers, and daycare providers. Rapid identification of this pathogen is critical in cases of outbreaks, and empirical treatment with broad-spectrum antibiotics may lead to more severe disease. We have developed an assay that allows for the simultaneous identification of E. coli O157:H7 and determination of its antibiotic susceptibility.
Methods: N-ASSAY
Methods Details Classified until June 2017
Results: O157:H7 was detected at and above 10^6 bacteria/ml following a 30-minute incubation, with no interference by other tested bacteria. By increasing the incubation time to 6 hours, the sensitivity of the test increased to 10^1 bacteria/ml. In addition, incubation with ceftriaxone during this six-hour time period showed inhibition of growth.
Summary: This assay allows for the rapid detection of a high inoculum of E. coli O157:H7, and sensitivity is increased following a six-hour incubation. Importantly, antibiotic susceptibility may be determined during this six-hour incubation.
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
May 8, 2017
Additional TB Test Kits ordered for Third World Gates Foundation Project
NanoLogix is pleased to announce that they have just (8 May 2017) received a new order for double the amount of their TB Diagnostic test kits delivered in April for use on a Third World research project funded by the National Institutes of Health, (NIH) the National Institute of Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation, with other funding from foreign Government agencies.
Since the request from the project representative stated that it is imperative the kits be delivered as soon as possible, NanoLogix is shipping the kits for Wednesday delivery. While the total sales amounts for the TB kits is in the thousands of dollars, Nanologix hopes the sales for use in this and other related TB projects will grow significantly.
The technology used in the NanoLogix TB Test Kit is our BNP sandwiched-membrane technology. The use of the TB kit is to provide evidence of the presence of active (live) TB bacteria in a patient sample in 4-6 days rather than 3-5 weeks or more. The results from the NanoLogix TB tests are then processed through PCR (DNA testing) and other means to further define the identity of the TB. The original research paper citing the detection results and potential of pairing the NanoLogix technology with other technologies is available through this link:
https://www.omicsonline.org/1948-5948/JMBT-04-147.digital/JMBT-04-147.html
Related to this work, NanoLogix has received a request to pursue development of an N-Assay modified ELISA for detection and identification of TB. We will be doing so upon receipt of sufficient funding for that goal.
In other news, patent work on either/both FlatPack and N-Assay patent applications has reached the stage where final examinations have been requested in Mexico, Canada, South Korea, and Brazil. Notification of FlatPack Patent Grant was received last week from Chile.
May 4, 2017
TB test Kits for use in Third World Gates Foundation Project
NanoLogix is pleased to elaborate further on an item of note from last month's announcement regarding shipment of TB Diagnostic kits to a Third World Research Project. The Company has sold and shipped their TB Diagnostic test kits for use on a Third World research project funded by the National Institutes of Health, (NIH) the National Institute of Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation, with other funding from foreign Government agencies.
Three reasons exist for this announcement. The first is to inform the public that whenever we released previous news where we were either named as being associated in research and development by an entity such as the US EPA or the University of Texas Health Science Center in Houston, or were cited in a research paper dealing with our technology by Battelle Biomedical Research Center in Ohio, those entities were all harassed by persons claiming to be NanoLogix shareholders who demanded to know the nature of the business relationships between the entities and NanoLogix and who asked for insider information regarding the status of the ongoing research. Those harassing efforts nearly destroyed the ongoing business relationships NanoLogix was truly privileged to have with those organizations. In this case anyone pursuing the same tact will come up against some very non-receptive forces.
The second is to demonstrate that we at NanoLogix had a goal, and that was to develop and provide to the world, diagnostic and research technologies that are premier and second to none, to create jobs in the rust belt area of northeast Ohio where the mindset of the area is steel mills, auto manufacturing, and low tech service jobs.
The third is to call attention to the facts that we, being a penny stock company, are considered the lowest of the low for investment. We are ignored by brokerages, especially ignored by the local media, and scorned by the investment community in general. Oddly enough, as ignored as we've been, we have still developed customized versions of our new N-Assay modified ELISA rapid bacteria diagnostic for one of the World's largest medical technology companies (under a very strong non-disclosure agreement), worked with the US EPA on developing tests for drinking and source waters, and had our technology presented as the fastest, most accurate and sensitive bacteria diagnostic test in the world. In addition, we've sold large numbers of proprietary packed FlatPacked petri plates in the USA and around the world for use in everything from simple quality control, food processing monitoring, soil testing, cosmetics and personal care products testing, environmental testing for post-flood contamination, water quality analysis, biodefense (we think, but classified), university research, and tens of thousands of users through Amazon and EBay for varied uses.
...and now we've sold TB diagnostics for use on a project funded by whom...?
Our share price and company are under attack by sick manipulators who only hurt dedicated shareholders. We as a company will survive and prosper.
We will expand our facilities as soon as feasible for increased FlatPack and N-Assay production, and are exploring relocating to a different state where we can be considered as bringing a benefit to the area.
Apr. 28, 2017
NanoLogix N-Assay Bacteria Diagnostic Technology for Rare Deinococcus Bacteria to be presented at AACC Annual Meeting in San Diego:
NanoLogix is pleased to announce that the N-Assay Bacteria Diagnostic, recently configured for detection and identification of a rare Deinococcus bacteria species will be presented in poster format at the American Association for Clinical Chemistry (AACC) 69th Annual Scientific Meeting and Clinical Lab Expo, to be held at the San Diego Convention Center in San Diego, California from July 30th through August 3rd, 2017. Dr. Jonathan Faro, MD, PhD and others associated with the development will be present for the poster session.
NanoLogix personnel are exploring the potential of staffing an exhibit booth at the event to display both the new modified-ELISA N-Assay diagnostic kit and also the FlatPack extended shelf life technology for petri plates.
The N-Assay Diagnostic furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus.
The published research results may be accessed through this link:
http://dx.doi.org/10.1155/2016/5293034
The AACC Deinococcus poster presentation illustrates how the N-Assay reduces the detection and identification times from roughly two weeks to a few days, with improved sensitivities over any other known test method.
Further information as to poster display and potential exhibit booth location will be made available in the near future when supplied to us by the AACC. Currently, general information for the event may be found by following this link:
https://www.aacc.org/meetings-and-events/2017-annual-meeting/clinical-lab-expo
The N-Assay Diagnostic for eColi will also be presented at the ASM Microbe 2017 in New Orleans June 1-5. Information for that event is available here:
https://www.asm.org/index.php/asm-microbe-2017
Apr. 4, 2017
NanoLogix has shipped TB test Kits for use in Third World Project
NanoLogix is pleased to announce items of note that have occurred this week. The first is that the Company has sold and shipped their TB Diagnostic test kits for use on a Third World research project funded by multiple US Federal and foreign Government agencies and a large international philanthropic organization. Once the project results are published we will be at liberty to elaborate further. The second item is that the Company today received the largest single delivery to date of petri plates for continued production of prepoured agar-filled FlatPacks, taking delivery of 150,000 sterilized petri plates.
Mar. 16, 2017
NanoLogix N-Assay Bacteria Diagnostic Technology for E. coli to be presented at June ASM Annual Meeting in New Orleans:
NanoLogix is pleased to announce that the N-Assay Bacteria Diagnostic, newly configured for E. coli will be presented in poster format at the American Society for Microbiology ASM Microbe 2017 to be held at the Ernest N. Morial Convention Center in New Orleans, Louisiana from June 1st through 5th. Dr. Sebastian Faro, MD, PhD and others associated with the development will be present for the poster session.
NanoLogix personnel are planning to staff an exhibit booth at the event to display both the Company-offered FlatPack for petri plates and the new N-Assay diagnostic. The FlatPack technology is becoming the premier petri plate storage method for those interested in long life room-temperature storage of prepared agar, with basic poured agars usable in as-new condition after 2-4 years of non-refrigerated storage. The NanoLogix FlatPack is available through www.nanologix.com and also on Amazon.com through two companies --- Evviva Scientific and Diamante Scientific.
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
Further information as to poster display and exhibit booth location will be made available in the near future when supplied to us by the ASM.
Mar. 2, 2017
NanoLogix is pleased to present a further update on the N-Assay Bacteria Diagnostic Technology:
After testing with customized N-Assay kits we supplied in January, the large medical technology client referenced in earlier updates has requested quotes from NanoLogix for expansion and further development using the N-Assay technology to detect additional bacteria species and genera.
Nanologix personnel and associates are excited to work with one of the World's largest medical companies on these N-Assay customizations. Due to a confidentiality agreement with our client, we cannot currently disclose the client identity.
There still remains the step of an independent time and sensitivity study for NanoLogix prior to marketing and sales for clinical use of the N-Assay. Personnel at a number of hospitals are reviewing potential study participation.
Jan. 9, 2017
NanoLogix is pleased to present a brief update on the N-Assay Bacteria Diagnostic Technology:
The N-Assay takes its place on our FDA medical device listing:
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm?lid=469637&lpcd=LIB
There is the remaining step of an independent time and sensitivity study for NanoLogix prior to marketing and sales for clinical use of the N-Assay.
NanoLogix has supplied all of the initially contracted and customized N-Assay kits to our multi-billion dollar medical technology client and we are awaiting results of their global testing.
Dec. 20, 2016
NanoLogix is pleased to announce the following Update:
The Company has narrowed its selection of buildings to use as a larger production facility in northeast Ohio. Two existing buildings are now under consideration to house NanoLogix production for both petri plates and for production of the new N-Assay ELISA-based rapid bacteria diagnostic. The projected expenditure for establishing N-Assay production and increasing petri plate production is roughly $900,000 for production equipment, $125,000 for the construction of two separate 70' X 30' production cleanrooms, and $40,000 for additional equipment such as forklifts.
This expansion is projected to result in market share increase for petri plate sales due to markedly improved economies of scale, and position NanoLogix with a significant production capability for the new N-Assay modified ELISA comprehensive bacteria diagnostic kit. The Company expects the expansion will result in ten additional jobs starting with the delivery and setup of the production equipment in 2017 and another ten positions upon expansion of N-Assay sales.
Over the coming six months we expect to finance the expansion through a combination of increasing revenue from sales of both product lines and fundraising through our current SEC Regulation D, Rule 506 offering for private placement sales of shares.
Any share issuance financing for this expansion is being structured primarily, but not solely, through a series of equity tranches and stock warrants. Using this method, the Company hopes to keep stock dilution to a minimum and will proceed with the interests of the shareholders in mind, including extending the timeline for expansion as necessary if equity costs are not favorable to NanoLogix.
The Company is preparing to seek licensees in Europe and Hong Kong for production of FlatPack Petri Plates under the recent EU FlatPack patent approval.
In response to queries coming to our office regarding our customization of the N-Assay for a multibillion medical technology company: we have sold 600+ of the N-Assay to them and will be supplying more in addition to further customization for other bacteria in 2017. As our arrangement with the client is CONFIDENTIAL, we will not be releasing their name.
Merry Christmas from Carol, Debby, Kim, Travis, Bret and all
Dec. 6, 2016
NanoLogix is pleased to announce the following Update:
The Company is currently searching for a larger production facility in northeast Ohio. In the past three weeks NanoLogix management and production staff have viewed, toured, and measured four separate sites to ascertain site suitability for relocating and expanding NanoLogix production for both petri plates and for production of the new N-Assay ELISA-based rapid bacteria diagnostic.
The new sites being surveyed range from 10,000 square feet to 22,000 square feet, three to seven times the size of our current facility. All sites viewed offer additional square footage for further expansion as required.
NanoLogix is also in the process of specifying and ordering new equipment for the production of both petri plates and the new N-Assay.
The two petri plate filling machines that have been configured for order are both OnlineEngineering MultiDish Model 968 with ancillary equipment. The Model 968 is capable of filling 9,600 plates per hour, so the two machines should be capable of meeting production needs for the forseeable future. Further information on the equipment can be found at: www.online-engineering.com
The N-Assay equipment currently being researched and specified are automatic pippetting machines for application of antibodies, etc., to the ELISA plates used for this revolutionary rapid bacteria diagnostic technology.
The two technologies will be housed in separate modular cleanrooms in order to comply with specific FDA requirements for manufacturing of each product.
The projected timeline for delivery and assembly of modular cleanrooms, the OnlineEngineering equipment, and the automated pippetting machines is sometime in the second quarter of 2017, while configuration of whichever of the candidate sites is chosen is projected to begin in the first quarter of 2017.
Petri plate production is currently in Hubbard, Ohio, while N-Assay production is in Houston, Texas. N-Assay production in Ohio is projected to begin in the second quarter of 2017.
------------------------------------------------------------------------------------------------------------------------------
Updates are available by signing up for eNews on the company's homepage at nanologix.com.
Development of a Novel Assay for the Simultaneous Identification of Deinococcus radiodurans and Determination of Susceptibility to a Selected Antibiotic
J. Faro, G. Riddle, S. Faro. The Woman’s Hospital of Texas, Houston, TX
Objective: To examine the ability of a novel diagnostic ELISA to identify Deinococcus radiodurans in a reduced time when compared to culture. D. radiodurans is a relatively new bacteria, first discovered in spoiled food which had first been irradiated. Although slow growing, the bacterium has been shown to be very resistant to radiation, extremes in temperature, and dehydration. As culture of this organism may take up to two weeks, food and beverage handlers, as well as medical device manufactures, would benefit greatly from an assay that allows for more rapid detection of D. radiodurans.
Methods: Microtiter wells were coated with polyclonal IgG rabbit antibody directed against D. radiodurans at a dilution of 1:50 in coating buffer. After 120 minutes, wells were emptied and then blocked with StartingBockTM. After blocking for 30 min, wells were emptied, and then bacterial isolates were added. For the 30-minute test, a series of dilutions of D. radiodurans were prepared in PBS, starting at 107 bacteria/ml, and diluting out ten-fold to 100 bacteria/ml. Samples were either run with D. radiodurans alone, or in the presence of other selected bacteria (Staphylococcus aureus, Enterococcus faecalis, Gordonia, Streptococcus agalactieae, Kocuria, Roseamonas) all at 107 bacteria/ml. In order to increase the limit of detection, D. radiodurans dilutions were prepared in FastidiousBrothTM, and cultured for predetermined lengths of time. After this culture period, samples were added to microtiter wells diluted 1:1 in phosphate buffered saline (PBS), and allowed to stand at room temperature for 30 minutes. Following this incubation step, wells were washed, and then bound bacteria was detected with HRP-conjugated anti-D. radiodurans antibody at 1:50 dilution for 20 minutes at room temperature. Wells were then washed, and signal was generated with TMB solution. Optical density was read at 450 nm. In order to determine antibiotic susceptibility, D. radiodurans dilutions were incubated for 72 hours in increasing concentrations of Cefazolin, starting at 0.08 ?g/ ml, and increasing up to 32 µg/ml. Cefazolin was selected from a panel of antibiotics which were shown to promote inhibition of growth by in-house turbidity assays.
Results: Following a 30-minute incubation in PBS, D. radiodurans was detected at a limit of 106 bacteria/ml. No interference was observed with any of the other bacteria tested. By increasing the incubation time in broth, the limit of detection increased to 105 bacteria/ml at 24 hours, 104 bacteria/ml at 48 hours, and 101 bacteria/ml following 72 hours. When dilutions of D. radiodurans were prepared in the presence of Cefazolin, the limit of detection (LoD) decreased as the antibiotic concentration increased: with 0.08 µg/ml Cefazolin, the LoD was 102 bacteria/ml; with 0.8 µg/ml Cefazolin, the LoD was 104 bacteria/ml, and with 8 µg/ml Cefazolin, the LoD was 106 bacteria/ml; following 72-hour incubation.
Conclusion: This novel assay allows for the simultaneous identification D. radiodurans and determination of antibiotic susceptibility in as little as 72 hours.
----------------------------------------------------------------------------------------------------------------------------------
H/T to mitstevfel at another board.
I think you're being intentionally obtuse at this point. I've already stated I thought the lack of cash flow/revenue was related to the patent, and not the company selling the patent.
I'm not going to Google away for something which I don't know even exists because you didn't unambiguously phrase a sentence at the start of all of this, especially since when I asked you a question some time ago about patents you just called me uneducated and basically told me to pound sand.
But if you make it interesting and put your handle on the line I will see what I can find, if anything.
And I don't think NNLX will sell their patents for anywhere close to their asking price. This is something I have already said here.
Well my offer stands. EOM
This is what you asked:
Absolutely not. I know of no business that manufactures a high valuation of a patent that created no cash flow and was successful at selling it.
This is what you said the second time:
show me an example where a company with NO REVENUE sold a patent for a large sum such as nanologix is trying to sell.
In the second instance it's been made clear it is a company with no revenue trying to sell a patent. In the first instance I took it to mean a patent that created cash flow.
Anyways, I think you were properly dealt with by drugmanrx. But if you want another example of a company which has generated next to no cash flow that sold a patent for $50 million or more I would be willing to bet my iHub account on it that I could produce one (i.e., delete my account if I am unable), if you're willing to bet yours.
If you had arranged your question like that initially I would have known what you had meant.
*fatality*
Company Updates
July 12, 2017
NanoLogix Offers EU, Hong Kong & PRC Petri FlatPack Packaging Patents For $35 - $50 Million
HUBBARD, Ohio, July 12, 2017 (GLOBE NEWSWIRE) -- NanoLogix (OTC:NNLX) is pleased to announce the offer for sale of the patents issued in the EU, Hong Kong (Patent EP269949), and the People's Republic of China (PRC Patent CN103842265 (B)) for their unique and exclusively licensed petri plate packaging system known as the FlatPack.
The FlatPack, a method of vacuum-packing for petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.
The FlatPack Patent has been granted in the USA, Mexico, New Zealand, South Africa, the EU (40 Patent signatory countries including Hong Kong), the People's Republic of China, and Chile, and is pending in South Korea, Brazil, and Canada.
The offering price range is cited as the estimate of value for the PRC patent ($35mm) and the EU patent ($15mm). Any interest in patent purchase for the other international granted patents is open for discussion.
A research paper by a renowned Biomedical Research Center on the qualities of FlatPack petri plates in a comparison test with competitors can be accessed here:
http://medcraveonline.com/JMEN/JMEN-03-00075.pdf
The decision for patent sale was made based upon the challenges faced in going forward with international development for NanoLogix, basically an R&D company for most of its existence with FlatPack petri sales limited to the US, the UK, and South Africa, versus focusing upon a more easily accessed domestic market and leaving the international market to those large corporations already operating in that environment.
Sales proceeds will be used for NanoLogix expansion of petri production and sales domestically and development and marketing of their N-Assay Rapid Bacteria Diagnostic Test. The N-Assay provides the most rapid and sensitive diagnostic for bacteria available, coupled with near-simultaneous determination of antibiotic sensitivity.
July 5, 2017
Mexico FlatPack Patent Granted
NanoLogix is extremely pleased to have received notification of grant from the Mexico Patent Office for their unique and exclusively licensed petri plate plate packaging system known as the FlatPack. The FlatPack, a method of vacuum-packing of petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.
This Mexico patent grant follows FlatPack patent grants in the USA, Peoples Republic of China, South Africa, New Zealand, Chile, and the European Union, to include Hong Kong.
A research paper by a renowned Biomedical Research Center on the qualities of FlatPacked petri plates in a comparison test with competitors can be accessed here:
http://medcraveonline.com/JMEN/JMEN-03-00075.pdf
For reference, this patent took nearly 5-1/2 years to be issued from the date of Patent Cooperation Treaty (PCT) filing.
June 22, 2017
EU, Hong Kong & PRC FlatPack Packaging Patents Offered For Sale
NanoLogix is pleased to announce the offer for sale of the patents issued in the EU, Hong Kong, and the Peoples Republic of China for their unique and exclusively licensed petri plate packaging system known as the FlatPack. The FlatPack, a method of vacuum-packing of petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.
A research paper by a renowned Biomedical Research Center on the qualities of FlatPacked petri plates in a comparison test with competitors can be accessed here:
http://medcraveonline.com/JMEN/JMEN-03-00075.pdf
The decision for patent sale was made based upon the challenges faced in going forward with international development for Nanologix, basically an R&D company for most of its existence with Flatpack Petri sales limited to the US, the UK, and South Africa, versus focusing upon a more easily accessed domestic market and leaving the international market to those large corporations already operating in that environment.
The proceeds from the sales are to be used to expand NanoLogix petri plate production in North America, development of an additional 30+ types of the N-Assay modified ELISA Rapid bacteria detection & identification kits, and other new biotechnology development related to antibody and aptamer use in diagnostics.
June 8, 2017
EU & Hong Kong FlatPack Patent Issued
NanoLogix is extremely pleased to announce the patent issuance on 7 June 2017 in the EU and Hong Kong for their unique and exclusively licensed petri plate plate packaging system known as the FlatPack. The FlatPack, a method of vacuum-packing of petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.
A PDF of the issued patent may be viewed here:
http://www.freepatentsonline.com/EP2699491.pdf
A research paper by a renowned Biomedical Research Center on the qualities of FlatPacked petri plates in a comparison test with competitors can be accessed here:
http://medcraveonline.com/JMEN/JMEN-03-00075.pdf
NanoLogix' intention is to register and validate the patent in most of the 40 EU member nations and patent treaty affiliates in addition to Hong Kong. Following that process, NanoLogix intends to seek licencee(s) for manufacturing and marketing for the those areas.
For reference: The patent process from the date of filing to issuance took five years and two months.
June 5, 2017
Reception of the NanoLogix N-Assay Bacteria Diagnostic Technology Poster for E. coli Presented at the American Society for Microbiology (ASM Microbe) Annual meeting
Novel Rapid Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of E. coli O157:H7
Jonathan Faro, MD, PhD and Sebastian Faro, MD, PhD, medical researchers presenting the technology poster at the ASM Annual meeting in New Orleans this past weekend stated:
"ASM Microbe was a very stimulating meeting. We enjoyed meeting many investigators and the engaging discussions that followed. Of the many rapid ID tests either on the market or the many more that presented and will soon be available, our assay is the most unique, and has the ability to provide the greatest limit of detection while simultaneously determining antibiotic susceptibility."
Further information from NanoLogix metrics monitoring indicated interest from at least two major laboratories.
The N-Assay is currently undergoing development for rapid detection of Urinary Tract Infections (UTI) and we anticipate the N-Assay to be debuted soon as the definitive UTI test for speed, accuracy, and sensitivity.
Two published examples of the N-Assay and its performance can be accessed through the following links:
https://www.hindawi.com/journals/idog/2016/5293034/
http://nanologix.com/news/poster-e-coli-0157.pdf
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B
Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
June 2, 2017
Update: NanoLogix N-Assay Bacteria Diagnostic Technology Poster for E. coli To Be Presented Tomorrow at the American Society for Microbiology (ASM) in New Orleans
Novel Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of E. coli O157:H7
This poster presentation will occur Saturday, June 3rd from 12:15 to 14:15 at position #456 in the category of Diagnostic Bacteriology III.
http://nanologix.com/news/poster-e-coli-0157.pdf
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
June 1, 2017
NanoLogix TB Detection Technology Use on Africa Project Increases
NanoLogix is pleased to announce that this week they shipped a new order for their TB Diagnostic test kits for use on an Africa research project funded by the National Institutes of Health, (NIH) the National Institute of Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation, with other funding from US and foreign Government agencies.
This is the third order since April on the Africa Project. NanoLogix was informed that in addition to the two sizes of kits sold in this order (150 mm and 100 mm), NanoLogix should prepare to supply two additional sizes of TB detection kits and also to significantly scale up TB kit production to satisfy projected needs.
For reference from an earlier update: "The technology used in the NanoLogix TB Test Kit is our BNP sandwiched-membrane technology. The use of the TB kit is to provide evidence of the presence of active (live) TB bacteria in a patient sample in 4-6 days rather than 3-5 weeks or more. The results from the NanoLogix TB tests are then processed through PCR (DNA testing) and other means to further define the identity of the TB. The original research paper citing the detection results and potential of pairing the NanoLogix technology with other technologies is available through this link:
https://www.omicsonline.org/1948-5948/JMBT-04-147.digital/JMBT-04-147.html
Related to this work, NanoLogix has received a request to pursue development of an N-Assay modified ELISA for detection and identification of TB. We will be doing so upon receipt of sufficient funding for that goal."
May 19, 2017
NanoLogix N-Assay Bacteria Diagnostic Technology for E. coli limited abstract
Novel Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of E. coli O157:H7
Novel Immunoassay for E coli O157:H7
Researchers: Classified until June 2017
Introduction: E. coli O157:H7 is associated with enterohemorrhagic infections, and is a concern for healthcare providers, food-handlers, and daycare providers. Rapid identification of this pathogen is critical in cases of outbreaks, and empirical treatment with broad-spectrum antibiotics may lead to more severe disease. We have developed an assay that allows for the simultaneous identification of E. coli O157:H7 and determination of its antibiotic susceptibility.
Methods: N-ASSAY
Methods Details Classified until June 2017
Results: O157:H7 was detected at and above 10^6 bacteria/ml following a 30-minute incubation, with no interference by other tested bacteria. By increasing the incubation time to 6 hours, the sensitivity of the test increased to 10^1 bacteria/ml. In addition, incubation with ceftriaxone during this six-hour time period showed inhibition of growth.
Summary: This assay allows for the rapid detection of a high inoculum of E. coli O157:H7, and sensitivity is increased following a six-hour incubation. Importantly, antibiotic susceptibility may be determined during this six-hour incubation.
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
May 8, 2017
Additional TB Test Kits ordered for Third World Gates Foundation Project
NanoLogix is pleased to announce that they have just (8 May 2017) received a new order for double the amount of their TB Diagnostic test kits delivered in April for use on a Third World research project funded by the National Institutes of Health, (NIH) the National Institute of Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation, with other funding from foreign Government agencies.
Since the request from the project representative stated that it is imperative the kits be delivered as soon as possible, NanoLogix is shipping the kits for Wednesday delivery. While the total sales amounts for the TB kits is in the thousands of dollars, Nanologix hopes the sales for use in this and other related TB projects will grow significantly.
The technology used in the NanoLogix TB Test Kit is our BNP sandwiched-membrane technology. The use of the TB kit is to provide evidence of the presence of active (live) TB bacteria in a patient sample in 4-6 days rather than 3-5 weeks or more. The results from the NanoLogix TB tests are then processed through PCR (DNA testing) and other means to further define the identity of the TB. The original research paper citing the detection results and potential of pairing the NanoLogix technology with other technologies is available through this link:
https://www.omicsonline.org/1948-5948/JMBT-04-147.digital/JMBT-04-147.html
Related to this work, NanoLogix has received a request to pursue development of an N-Assay modified ELISA for detection and identification of TB. We will be doing so upon receipt of sufficient funding for that goal.
In other news, patent work on either/both FlatPack and N-Assay patent applications has reached the stage where final examinations have been requested in Mexico, Canada, South Korea, and Brazil. Notification of FlatPack Patent Grant was received last week from Chile.
May 4, 2017
TB test Kits for use in Third World Gates Foundation Project
NanoLogix is pleased to elaborate further on an item of note from last month's announcement regarding shipment of TB Diagnostic kits to a Third World Research Project. The Company has sold and shipped their TB Diagnostic test kits for use on a Third World research project funded by the National Institutes of Health, (NIH) the National Institute of Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation, with other funding from foreign Government agencies.
Three reasons exist for this announcement. The first is to inform the public that whenever we released previous news where we were either named as being associated in research and development by an entity such as the US EPA or the University of Texas Health Science Center in Houston, or were cited in a research paper dealing with our technology by Battelle Biomedical Research Center in Ohio, those entities were all harassed by persons claiming to be NanoLogix shareholders who demanded to know the nature of the business relationships between the entities and NanoLogix and who asked for insider information regarding the status of the ongoing research. Those harassing efforts nearly destroyed the ongoing business relationships NanoLogix was truly privileged to have with those organizations. In this case anyone pursuing the same tact will come up against some very non-receptive forces.
The second is to demonstrate that we at NanoLogix had a goal, and that was to develop and provide to the world, diagnostic and research technologies that are premier and second to none, to create jobs in the rust belt area of northeast Ohio where the mindset of the area is steel mills, auto manufacturing, and low tech service jobs.
The third is to call attention to the facts that we, being a penny stock company, are considered the lowest of the low for investment. We are ignored by brokerages, especially ignored by the local media, and scorned by the investment community in general. Oddly enough, as ignored as we've been, we have still developed customized versions of our new N-Assay modified ELISA rapid bacteria diagnostic for one of the World's largest medical technology companies (under a very strong non-disclosure agreement), worked with the US EPA on developing tests for drinking and source waters, and had our technology presented as the fastest, most accurate and sensitive bacteria diagnostic test in the world. In addition, we've sold large numbers of proprietary packed FlatPacked petri plates in the USA and around the world for use in everything from simple quality control, food processing monitoring, soil testing, cosmetics and personal care products testing, environmental testing for post-flood contamination, water quality analysis, biodefense (we think, but classified), university research, and tens of thousands of users through Amazon and EBay for varied uses.
...and now we've sold TB diagnostics for use on a project funded by whom...?
Our share price and company are under attack by sick manipulators who only hurt dedicated shareholders. We as a company will survive and prosper.
We will expand our facilities as soon as feasible for increased FlatPack and N-Assay production, and are exploring relocating to a different state where we can be considered as bringing a benefit to the area.
Apr. 28, 2017
NanoLogix N-Assay Bacteria Diagnostic Technology for Rare Deinococcus Bacteria to be presented at AACC Annual Meeting in San Diego:
NanoLogix is pleased to announce that the N-Assay Bacteria Diagnostic, recently configured for detection and identification of a rare Deinococcus bacteria species will be presented in poster format at the American Association for Clinical Chemistry (AACC) 69th Annual Scientific Meeting and Clinical Lab Expo, to be held at the San Diego Convention Center in San Diego, California from July 30th through August 3rd, 2017. Dr. Jonathan Faro, MD, PhD and others associated with the development will be present for the poster session.
NanoLogix personnel are exploring the potential of staffing an exhibit booth at the event to display both the new modified-ELISA N-Assay diagnostic kit and also the FlatPack extended shelf life technology for petri plates.
The N-Assay Diagnostic furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus.
The published research results may be accessed through this link:
http://dx.doi.org/10.1155/2016/5293034
The AACC Deinococcus poster presentation illustrates how the N-Assay reduces the detection and identification times from roughly two weeks to a few days, with improved sensitivities over any other known test method.
Further information as to poster display and potential exhibit booth location will be made available in the near future when supplied to us by the AACC. Currently, general information for the event may be found by following this link:
https://www.aacc.org/meetings-and-events/2017-annual-meeting/clinical-lab-expo
The N-Assay Diagnostic for eColi will also be presented at the ASM Microbe 2017 in New Orleans June 1-5. Information for that event is available here:
https://www.asm.org/index.php/asm-microbe-2017
Apr. 4, 2017
NanoLogix has shipped TB test Kits for use in Third World Project
NanoLogix is pleased to announce items of note that have occurred this week. The first is that the Company has sold and shipped their TB Diagnostic test kits for use on a Third World research project funded by multiple US Federal and foreign Government agencies and a large international philanthropic organization. Once the project results are published we will be at liberty to elaborate further. The second item is that the Company today received the largest single delivery to date of petri plates for continued production of prepoured agar-filled FlatPacks, taking delivery of 150,000 sterilized petri plates.
Mar. 16, 2017
NanoLogix N-Assay Bacteria Diagnostic Technology for E. coli to be presented at June ASM Annual Meeting in New Orleans:
NanoLogix is pleased to announce that the N-Assay Bacteria Diagnostic, newly configured for E. coli will be presented in poster format at the American Society for Microbiology ASM Microbe 2017 to be held at the Ernest N. Morial Convention Center in New Orleans, Louisiana from June 1st through 5th. Dr. Sebastian Faro, MD, PhD and others associated with the development will be present for the poster session.
NanoLogix personnel are planning to staff an exhibit booth at the event to display both the Company-offered FlatPack for petri plates and the new N-Assay diagnostic. The FlatPack technology is becoming the premier petri plate storage method for those interested in long life room-temperature storage of prepared agar, with basic poured agars usable in as-new condition after 2-4 years of non-refrigerated storage. The NanoLogix FlatPack is available through www.nanologix.com and also on Amazon.com through two companies --- Evviva Scientific and Diamante Scientific.
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
Further information as to poster display and exhibit booth location will be made available in the near future when supplied to us by the ASM.
Mar. 2, 2017
NanoLogix is pleased to present a further update on the N-Assay Bacteria Diagnostic Technology:
After testing with customized N-Assay kits we supplied in January, the large medical technology client referenced in earlier updates has requested quotes from NanoLogix for expansion and further development using the N-Assay technology to detect additional bacteria species and genera.
Nanologix personnel and associates are excited to work with one of the World's largest medical companies on these N-Assay customizations. Due to a confidentiality agreement with our client, we cannot currently disclose the client identity.
There still remains the step of an independent time and sensitivity study for NanoLogix prior to marketing and sales for clinical use of the N-Assay. Personnel at a number of hospitals are reviewing potential study participation.
Jan. 9, 2017
NanoLogix is pleased to present a brief update on the N-Assay Bacteria Diagnostic Technology:
The N-Assay takes its place on our FDA medical device listing:
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm?lid=469637&lpcd=LIB
There is the remaining step of an independent time and sensitivity study for NanoLogix prior to marketing and sales for clinical use of the N-Assay.
NanoLogix has supplied all of the initially contracted and customized N-Assay kits to our multi-billion dollar medical technology client and we are awaiting results of their global testing.
Dec. 20, 2016
NanoLogix is pleased to announce the following Update:
The Company has narrowed its selection of buildings to use as a larger production facility in northeast Ohio. Two existing buildings are now under consideration to house NanoLogix production for both petri plates and for production of the new N-Assay ELISA-based rapid bacteria diagnostic. The projected expenditure for establishing N-Assay production and increasing petri plate production is roughly $900,000 for production equipment, $125,000 for the construction of two separate 70' X 30' production cleanrooms, and $40,000 for additional equipment such as forklifts.
This expansion is projected to result in market share increase for petri plate sales due to markedly improved economies of scale, and position NanoLogix with a significant production capability for the new N-Assay modified ELISA comprehensive bacteria diagnostic kit. The Company expects the expansion will result in ten additional jobs starting with the delivery and setup of the production equipment in 2017 and another ten positions upon expansion of N-Assay sales.
Over the coming six months we expect to finance the expansion through a combination of increasing revenue from sales of both product lines and fundraising through our current SEC Regulation D, Rule 506 offering for private placement sales of shares.
Any share issuance financing for this expansion is being structured primarily, but not solely, through a series of equity tranches and stock warrants. Using this method, the Company hopes to keep stock dilution to a minimum and will proceed with the interests of the shareholders in mind, including extending the timeline for expansion as necessary if equity costs are not favorable to NanoLogix.
The Company is preparing to seek licensees in Europe and Hong Kong for production of FlatPack Petri Plates under the recent EU FlatPack patent approval.
In response to queries coming to our office regarding our customization of the N-Assay for a multibillion medical technology company: we have sold 600+ of the N-Assay to them and will be supplying more in addition to further customization for other bacteria in 2017. As our arrangement with the client is CONFIDENTIAL, we will not be releasing their name.
Merry Christmas from Carol, Debby, Kim, Travis, Bret and all
Dec. 6, 2016
NanoLogix is pleased to announce the following Update:
The Company is currently searching for a larger production facility in northeast Ohio. In the past three weeks NanoLogix management and production staff have viewed, toured, and measured four separate sites to ascertain site suitability for relocating and expanding NanoLogix production for both petri plates and for production of the new N-Assay ELISA-based rapid bacteria diagnostic.
The new sites being surveyed range from 10,000 square feet to 22,000 square feet, three to seven times the size of our current facility. All sites viewed offer additional square footage for further expansion as required.
NanoLogix is also in the process of specifying and ordering new equipment for the production of both petri plates and the new N-Assay.
The two petri plate filling machines that have been configured for order are both OnlineEngineering MultiDish Model 968 with ancillary equipment. The Model 968 is capable of filling 9,600 plates per hour, so the two machines should be capable of meeting production needs for the forseeable future. Further information on the equipment can be found at: www.online-engineering.com
The N-Assay equipment currently being researched and specified are automatic pippetting machines for application of antibodies, etc., to the ELISA plates used for this revolutionary rapid bacteria diagnostic technology.
The two technologies will be housed in separate modular cleanrooms in order to comply with specific FDA requirements for manufacturing of each product.
The projected timeline for delivery and assembly of modular cleanrooms, the OnlineEngineering equipment, and the automated pippetting machines is sometime in the second quarter of 2017, while configuration of whichever of the candidate sites is chosen is projected to begin in the first quarter of 2017.
Petri plate production is currently in Hubbard, Ohio, while N-Assay production is in Houston, Texas. N-Assay production in Ohio is projected to begin in the second quarter of 2017.
------------------------------------------------------------------------------------------------------------------------------
Updates are available by signing up for eNews on the company's homepage at nanologix.com.
Omar, I agree. As another poster pointed out here or perhaps another board, with overnight shipping it would seem that the advantages of a long shelf-life would only be advantageous in the third world. I hope I am proven wrong but I would be surprised if NNLX gets anything close to its asking price for the patents.
Company Updates
July 5, 2017
Mexico FlatPack Patent Granted
NanoLogix is extremely pleased to have received notification of grant from the Mexico Patent Office for their unique and exclusively licensed petri plate plate packaging system known as the FlatPack. The FlatPack, a method of vacuum-packing of petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.
This Mexico patent grant follows FlatPack patent grants in the USA, Peoples Republic of China, South Africa, New Zealand, Chile, and the European Union, to include Hong Kong.
A research paper by a renowned Biomedical Research Center on the qualities of FlatPacked petri plates in a comparison test with competitors can be accessed here:
http://medcraveonline.com/JMEN/JMEN-03-00075.pdf
For reference, this patent took nearly 5-1/2 years to be issued from the date of Patent Cooperation Treaty (PCT) filing.
June 22, 2017
EU, Hong Kong & PRC FlatPack Packaging Patents Offered For Sale
NanoLogix is pleased to announce the offer for sale of the patents issued in the EU, Hong Kong, and the Peoples Republic of China for their unique and exclusively licensed petri plate packaging system known as the FlatPack. The FlatPack, a method of vacuum-packing of petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.
A research paper by a renowned Biomedical Research Center on the qualities of FlatPacked petri plates in a comparison test with competitors can be accessed here:
http://medcraveonline.com/JMEN/JMEN-03-00075.pdf
The decision for patent sale was made based upon the challenges faced in going forward with international development for Nanologix, basically an R&D company for most of its existence with Flatpack Petri sales limited to the US, the UK, and South Africa, versus focusing upon a more easily accessed domestic market and leaving the international market to those large corporations already operating in that environment.
The proceeds from the sales are to be used to expand NanoLogix petri plate production in North America, development of an additional 30+ types of the N-Assay modified ELISA Rapid bacteria detection & identification kits, and other new biotechnology development related to antibody and aptamer use in diagnostics.
June 8, 2017
EU & Hong Kong FlatPack Patent Issued
NanoLogix is extremely pleased to announce the patent issuance on 7 June 2017 in the EU and Hong Kong for their unique and exclusively licensed petri plate plate packaging system known as the FlatPack. The FlatPack, a method of vacuum-packing of petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.
A PDF of the issued patent may be viewed here:
http://www.freepatentsonline.com/EP2699491.pdf
A research paper by a renowned Biomedical Research Center on the qualities of FlatPacked petri plates in a comparison test with competitors can be accessed here:
http://medcraveonline.com/JMEN/JMEN-03-00075.pdf
NanoLogix' intention is to register and validate the patent in most of the 40 EU member nations and patent treaty affiliates in addition to Hong Kong. Following that process, NanoLogix intends to seek licencee(s) for manufacturing and marketing for the those areas.
For reference: The patent process from the date of filing to issuance took five years and two months.
June 5, 2017
Reception of the NanoLogix N-Assay Bacteria Diagnostic Technology Poster for E. coli Presented at the American Society for Microbiology (ASM Microbe) Annual meeting
Novel Rapid Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of E. coli O157:H7
Jonathan Faro, MD, PhD and Sebastian Faro, MD, PhD, medical researchers presenting the technology poster at the ASM Annual meeting in New Orleans this past weekend stated:
"ASM Microbe was a very stimulating meeting. We enjoyed meeting many investigators and the engaging discussions that followed. Of the many rapid ID tests either on the market or the many more that presented and will soon be available, our assay is the most unique, and has the ability to provide the greatest limit of detection while simultaneously determining antibiotic susceptibility."
Further information from NanoLogix metrics monitoring indicated interest from at least two major laboratories.
The N-Assay is currently undergoing development for rapid detection of Urinary Tract Infections (UTI) and we anticipate the N-Assay to be debuted soon as the definitive UTI test for speed, accuracy, and sensitivity.
Two published examples of the N-Assay and its performance can be accessed through the following links:
https://www.hindawi.com/journals/idog/2016/5293034/
http://nanologix.com/news/poster-e-coli-0157.pdf
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B
Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
June 2, 2017
Update: NanoLogix N-Assay Bacteria Diagnostic Technology Poster for E. coli To Be Presented Tomorrow at the American Society for Microbiology (ASM) in New Orleans
Novel Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of E. coli O157:H7
This poster presentation will occur Saturday, June 3rd from 12:15 to 14:15 at position #456 in the category of Diagnostic Bacteriology III.
http://nanologix.com/news/poster-e-coli-0157.pdf
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
June 1, 2017
NanoLogix TB Detection Technology Use on Africa Project Increases
NanoLogix is pleased to announce that this week they shipped a new order for their TB Diagnostic test kits for use on an Africa research project funded by the National Institutes of Health, (NIH) the National Institute of Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation, with other funding from US and foreign Government agencies.
This is the third order since April on the Africa Project. NanoLogix was informed that in addition to the two sizes of kits sold in this order (150 mm and 100 mm), NanoLogix should prepare to supply two additional sizes of TB detection kits and also to significantly scale up TB kit production to satisfy projected needs.
For reference from an earlier update: "The technology used in the NanoLogix TB Test Kit is our BNP sandwiched-membrane technology. The use of the TB kit is to provide evidence of the presence of active (live) TB bacteria in a patient sample in 4-6 days rather than 3-5 weeks or more. The results from the NanoLogix TB tests are then processed through PCR (DNA testing) and other means to further define the identity of the TB. The original research paper citing the detection results and potential of pairing the NanoLogix technology with other technologies is available through this link:
https://www.omicsonline.org/1948-5948/JMBT-04-147.digital/JMBT-04-147.html
Related to this work, NanoLogix has received a request to pursue development of an N-Assay modified ELISA for detection and identification of TB. We will be doing so upon receipt of sufficient funding for that goal."
May 19, 2017
NanoLogix N-Assay Bacteria Diagnostic Technology for E. coli limited abstract
Novel Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of E. coli O157:H7
Novel Immunoassay for E coli O157:H7
Researchers: Classified until June 2017
Introduction: E. coli O157:H7 is associated with enterohemorrhagic infections, and is a concern for healthcare providers, food-handlers, and daycare providers. Rapid identification of this pathogen is critical in cases of outbreaks, and empirical treatment with broad-spectrum antibiotics may lead to more severe disease. We have developed an assay that allows for the simultaneous identification of E. coli O157:H7 and determination of its antibiotic susceptibility.
Methods: N-ASSAY
Methods Details Classified until June 2017
Results: O157:H7 was detected at and above 10^6 bacteria/ml following a 30-minute incubation, with no interference by other tested bacteria. By increasing the incubation time to 6 hours, the sensitivity of the test increased to 10^1 bacteria/ml. In addition, incubation with ceftriaxone during this six-hour time period showed inhibition of growth.
Summary: This assay allows for the rapid detection of a high inoculum of E. coli O157:H7, and sensitivity is increased following a six-hour incubation. Importantly, antibiotic susceptibility may be determined during this six-hour incubation.
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
May 8, 2017
Additional TB Test Kits ordered for Third World Gates Foundation Project
NanoLogix is pleased to announce that they have just (8 May 2017) received a new order for double the amount of their TB Diagnostic test kits delivered in April for use on a Third World research project funded by the National Institutes of Health, (NIH) the National Institute of Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation, with other funding from foreign Government agencies.
Since the request from the project representative stated that it is imperative the kits be delivered as soon as possible, NanoLogix is shipping the kits for Wednesday delivery. While the total sales amounts for the TB kits is in the thousands of dollars, Nanologix hopes the sales for use in this and other related TB projects will grow significantly.
The technology used in the NanoLogix TB Test Kit is our BNP sandwiched-membrane technology. The use of the TB kit is to provide evidence of the presence of active (live) TB bacteria in a patient sample in 4-6 days rather than 3-5 weeks or more. The results from the NanoLogix TB tests are then processed through PCR (DNA testing) and other means to further define the identity of the TB. The original research paper citing the detection results and potential of pairing the NanoLogix technology with other technologies is available through this link:
https://www.omicsonline.org/1948-5948/JMBT-04-147.digital/JMBT-04-147.html
Related to this work, NanoLogix has received a request to pursue development of an N-Assay modified ELISA for detection and identification of TB. We will be doing so upon receipt of sufficient funding for that goal.
In other news, patent work on either/both FlatPack and N-Assay patent applications has reached the stage where final examinations have been requested in Mexico, Canada, South Korea, and Brazil. Notification of FlatPack Patent Grant was received last week from Chile.
May 4, 2017
TB test Kits for use in Third World Gates Foundation Project
NanoLogix is pleased to elaborate further on an item of note from last month's announcement regarding shipment of TB Diagnostic kits to a Third World Research Project. The Company has sold and shipped their TB Diagnostic test kits for use on a Third World research project funded by the National Institutes of Health, (NIH) the National Institute of Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation, with other funding from foreign Government agencies.
Three reasons exist for this announcement. The first is to inform the public that whenever we released previous news where we were either named as being associated in research and development by an entity such as the US EPA or the University of Texas Health Science Center in Houston, or were cited in a research paper dealing with our technology by Battelle Biomedical Research Center in Ohio, those entities were all harassed by persons claiming to be NanoLogix shareholders who demanded to know the nature of the business relationships between the entities and NanoLogix and who asked for insider information regarding the status of the ongoing research. Those harassing efforts nearly destroyed the ongoing business relationships NanoLogix was truly privileged to have with those organizations. In this case anyone pursuing the same tact will come up against some very non-receptive forces.
The second is to demonstrate that we at NanoLogix had a goal, and that was to develop and provide to the world, diagnostic and research technologies that are premier and second to none, to create jobs in the rust belt area of northeast Ohio where the mindset of the area is steel mills, auto manufacturing, and low tech service jobs.
The third is to call attention to the facts that we, being a penny stock company, are considered the lowest of the low for investment. We are ignored by brokerages, especially ignored by the local media, and scorned by the investment community in general. Oddly enough, as ignored as we've been, we have still developed customized versions of our new N-Assay modified ELISA rapid bacteria diagnostic for one of the World's largest medical technology companies (under a very strong non-disclosure agreement), worked with the US EPA on developing tests for drinking and source waters, and had our technology presented as the fastest, most accurate and sensitive bacteria diagnostic test in the world. In addition, we've sold large numbers of proprietary packed FlatPacked petri plates in the USA and around the world for use in everything from simple quality control, food processing monitoring, soil testing, cosmetics and personal care products testing, environmental testing for post-flood contamination, water quality analysis, biodefense (we think, but classified), university research, and tens of thousands of users through Amazon and EBay for varied uses.
...and now we've sold TB diagnostics for use on a project funded by whom...?
Our share price and company are under attack by sick manipulators who only hurt dedicated shareholders. We as a company will survive and prosper.
We will expand our facilities as soon as feasible for increased FlatPack and N-Assay production, and are exploring relocating to a different state where we can be considered as bringing a benefit to the area.
Apr. 28, 2017
NanoLogix N-Assay Bacteria Diagnostic Technology for Rare Deinococcus Bacteria to be presented at AACC Annual Meeting in San Diego:
NanoLogix is pleased to announce that the N-Assay Bacteria Diagnostic, recently configured for detection and identification of a rare Deinococcus bacteria species will be presented in poster format at the American Association for Clinical Chemistry (AACC) 69th Annual Scientific Meeting and Clinical Lab Expo, to be held at the San Diego Convention Center in San Diego, California from July 30th through August 3rd, 2017. Dr. Jonathan Faro, MD, PhD and others associated with the development will be present for the poster session.
NanoLogix personnel are exploring the potential of staffing an exhibit booth at the event to display both the new modified-ELISA N-Assay diagnostic kit and also the FlatPack extended shelf life technology for petri plates.
The N-Assay Diagnostic furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus.
The published research results may be accessed through this link:
http://dx.doi.org/10.1155/2016/5293034
The AACC Deinococcus poster presentation illustrates how the N-Assay reduces the detection and identification times from roughly two weeks to a few days, with improved sensitivities over any other known test method.
Further information as to poster display and potential exhibit booth location will be made available in the near future when supplied to us by the AACC. Currently, general information for the event may be found by following this link:
https://www.aacc.org/meetings-and-events/2017-annual-meeting/clinical-lab-expo
The N-Assay Diagnostic for eColi will also be presented at the ASM Microbe 2017 in New Orleans June 1-5. Information for that event is available here:
https://www.asm.org/index.php/asm-microbe-2017
Apr. 4, 2017
NanoLogix has shipped TB test Kits for use in Third World Project
NanoLogix is pleased to announce items of note that have occurred this week. The first is that the Company has sold and shipped their TB Diagnostic test kits for use on a Third World research project funded by multiple US Federal and foreign Government agencies and a large international philanthropic organization. Once the project results are published we will be at liberty to elaborate further. The second item is that the Company today received the largest single delivery to date of petri plates for continued production of prepoured agar-filled FlatPacks, taking delivery of 150,000 sterilized petri plates.
Mar. 16, 2017
NanoLogix N-Assay Bacteria Diagnostic Technology for E. coli to be presented at June ASM Annual Meeting in New Orleans:
NanoLogix is pleased to announce that the N-Assay Bacteria Diagnostic, newly configured for E. coli will be presented in poster format at the American Society for Microbiology ASM Microbe 2017 to be held at the Ernest N. Morial Convention Center in New Orleans, Louisiana from June 1st through 5th. Dr. Sebastian Faro, MD, PhD and others associated with the development will be present for the poster session.
NanoLogix personnel are planning to staff an exhibit booth at the event to display both the Company-offered FlatPack for petri plates and the new N-Assay diagnostic. The FlatPack technology is becoming the premier petri plate storage method for those interested in long life room-temperature storage of prepared agar, with basic poured agars usable in as-new condition after 2-4 years of non-refrigerated storage. The NanoLogix FlatPack is available through www.nanologix.com and also on Amazon.com through two companies --- Evviva Scientific and Diamante Scientific.
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
Further information as to poster display and exhibit booth location will be made available in the near future when supplied to us by the ASM.
Mar. 2, 2017
NanoLogix is pleased to present a further update on the N-Assay Bacteria Diagnostic Technology:
After testing with customized N-Assay kits we supplied in January, the large medical technology client referenced in earlier updates has requested quotes from NanoLogix for expansion and further development using the N-Assay technology to detect additional bacteria species and genera.
Nanologix personnel and associates are excited to work with one of the World's largest medical companies on these N-Assay customizations. Due to a confidentiality agreement with our client, we cannot currently disclose the client identity.
There still remains the step of an independent time and sensitivity study for NanoLogix prior to marketing and sales for clinical use of the N-Assay. Personnel at a number of hospitals are reviewing potential study participation.
Jan. 9, 2017
NanoLogix is pleased to present a brief update on the N-Assay Bacteria Diagnostic Technology:
The N-Assay takes its place on our FDA medical device listing:
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm?lid=469637&lpcd=LIB
There is the remaining step of an independent time and sensitivity study for NanoLogix prior to marketing and sales for clinical use of the N-Assay.
NanoLogix has supplied all of the initially contracted and customized N-Assay kits to our multi-billion dollar medical technology client and we are awaiting results of their global testing.
Dec. 20, 2016
NanoLogix is pleased to announce the following Update:
The Company has narrowed its selection of buildings to use as a larger production facility in northeast Ohio. Two existing buildings are now under consideration to house NanoLogix production for both petri plates and for production of the new N-Assay ELISA-based rapid bacteria diagnostic. The projected expenditure for establishing N-Assay production and increasing petri plate production is roughly $900,000 for production equipment, $125,000 for the construction of two separate 70' X 30' production cleanrooms, and $40,000 for additional equipment such as forklifts.
This expansion is projected to result in market share increase for petri plate sales due to markedly improved economies of scale, and position NanoLogix with a significant production capability for the new N-Assay modified ELISA comprehensive bacteria diagnostic kit. The Company expects the expansion will result in ten additional jobs starting with the delivery and setup of the production equipment in 2017 and another ten positions upon expansion of N-Assay sales.
Over the coming six months we expect to finance the expansion through a combination of increasing revenue from sales of both product lines and fundraising through our current SEC Regulation D, Rule 506 offering for private placement sales of shares.
Any share issuance financing for this expansion is being structured primarily, but not solely, through a series of equity tranches and stock warrants. Using this method, the Company hopes to keep stock dilution to a minimum and will proceed with the interests of the shareholders in mind, including extending the timeline for expansion as necessary if equity costs are not favorable to NanoLogix.
The Company is preparing to seek licensees in Europe and Hong Kong for production of FlatPack Petri Plates under the recent EU FlatPack patent approval.
In response to queries coming to our office regarding our customization of the N-Assay for a multibillion medical technology company: we have sold 600+ of the N-Assay to them and will be supplying more in addition to further customization for other bacteria in 2017. As our arrangement with the client is CONFIDENTIAL, we will not be releasing their name.
Merry Christmas from Carol, Debby, Kim, Travis, Bret and all
Dec. 6, 2016
NanoLogix is pleased to announce the following Update:
The Company is currently searching for a larger production facility in northeast Ohio. In the past three weeks NanoLogix management and production staff have viewed, toured, and measured four separate sites to ascertain site suitability for relocating and expanding NanoLogix production for both petri plates and for production of the new N-Assay ELISA-based rapid bacteria diagnostic.
The new sites being surveyed range from 10,000 square feet to 22,000 square feet, three to seven times the size of our current facility. All sites viewed offer additional square footage for further expansion as required.
NanoLogix is also in the process of specifying and ordering new equipment for the production of both petri plates and the new N-Assay.
The two petri plate filling machines that have been configured for order are both OnlineEngineering MultiDish Model 968 with ancillary equipment. The Model 968 is capable of filling 9,600 plates per hour, so the two machines should be capable of meeting production needs for the forseeable future. Further information on the equipment can be found at: www.online-engineering.com
The N-Assay equipment currently being researched and specified are automatic pippetting machines for application of antibodies, etc., to the ELISA plates used for this revolutionary rapid bacteria diagnostic technology.
The two technologies will be housed in separate modular cleanrooms in order to comply with specific FDA requirements for manufacturing of each product.
The projected timeline for delivery and assembly of modular cleanrooms, the OnlineEngineering equipment, and the automated pippetting machines is sometime in the second quarter of 2017, while configuration of whichever of the candidate sites is chosen is projected to begin in the first quarter of 2017.
Petri plate production is currently in Hubbard, Ohio, while N-Assay production is in Houston, Texas. N-Assay production in Ohio is projected to begin in the second quarter of 2017.
------------------------------------------------------------------------------------------------------------------------------
Updates are available by signing up for eNews on the company's homepage at nanologix.com.
Company Updates
June 22, 2017
EU, Hong Kong & PRC FlatPack Packaging Patents Offered For Sale
NanoLogix is pleased to announce the offer for sale of the patents issued in the EU, Hong Kong, and the Peoples Republic of China for their unique and exclusively licensed petri plate packaging system known as the FlatPack. The FlatPack, a method of vacuum-packing of petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.
A research paper by a renowned Biomedical Research Center on the qualities of FlatPacked petri plates in a comparison test with competitors can be accessed here:
http://medcraveonline.com/JMEN/JMEN-03-00075.pdf
The decision for patent sale was made based upon the challenges faced in going forward with international development for Nanologix, basically an R&D company for most of its existence with Flatpack Petri sales limited to the US, the UK, and South Africa, versus focusing upon a more easily accessed domestic market and leaving the international market to those large corporations already operating in that environment.
The proceeds from the sales are to be used to expand NanoLogix petri plate production in North America, development of an additional 30+ types of the N-Assay modified ELISA Rapid bacteria detection & identification kits, and other new biotechnology development related to antibody and aptamer use in diagnostics.
June 8, 2017
EU & Hong Kong FlatPack Patent Issued
NanoLogix is extremely pleased to announce the patent issuance on 7 June 2017 in the EU and Hong Kong for their unique and exclusively licensed petri plate plate packaging system known as the FlatPack. The FlatPack, a method of vacuum-packing of petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.
A PDF of the issued patent may be viewed here:
http://www.freepatentsonline.com/EP2699491.pdf
A research paper by a renowned Biomedical Research Center on the qualities of FlatPacked petri plates in a comparison test with competitors can be accessed here:
http://medcraveonline.com/JMEN/JMEN-03-00075.pdf
NanoLogix' intention is to register and validate the patent in most of the 40 EU member nations and patent treaty affiliates in addition to Hong Kong. Following that process, NanoLogix intends to seek licencee(s) for manufacturing and marketing for the those areas.
For reference: The patent process from the date of filing to issuance took five years and two months
June 5, 2017
Reception of the NanoLogix N-Assay Bacteria Diagnostic Technology Poster for E. coli Presented at the American Society for Microbiology (ASM Microbe) Annual meeting
Novel Rapid Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of E. coli O157:H7
Jonathan Faro, MD, PhD and Sebastian Faro, MD, PhD, medical researchers presenting the technology poster at the ASM Annual meeting in New Orleans this past weekend stated:
"ASM Microbe was a very stimulating meeting. We enjoyed meeting many investigators and the engaging discussions that followed. Of the many rapid ID tests either on the market or the many more that presented and will soon be available, our assay is the most unique, and has the ability to provide the greatest limit of detection while simultaneously determining antibiotic susceptibility."
Further information from NanoLogix metrics monitoring indicated interest from at least two major laboratories.
The N-Assay is currently undergoing development for rapid detection of Urinary Tract Infections (UTI) and we anticipate the N-Assay to be debuted soon as the definitive UTI test for speed, accuracy, and sensitivity.
Two published examples of the N-Assay and its performance can be accessed through the following links:
https://www.hindawi.com/journals/idog/2016/5293034/
http://nanologix.com/news/poster-e-coli-0157.pdf
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B
Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
June 2, 2017
Update: NanoLogix N-Assay Bacteria Diagnostic Technology Poster for E. coli To Be Presented Tomorrow at the American Society for Microbiology (ASM) in New Orleans
Novel Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of E. coli O157:H7
This poster presentation will occur Saturday, June 3rd from 12:15 to 14:15 at position #456 in the category of Diagnostic Bacteriology III.
http://nanologix.com/news/poster-e-coli-0157.pdf
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
June 1, 2017
NanoLogix TB Detection Technology Use on Africa Project Increases
NanoLogix is pleased to announce that this week they shipped a new order for their TB Diagnostic test kits for use on an Africa research project funded by the National Institutes of Health, (NIH) the National Institute of Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation, with other funding from US and foreign Government agencies.
This is the third order since April on the Africa Project. NanoLogix was informed that in addition to the two sizes of kits sold in this order (150 mm and 100 mm), NanoLogix should prepare to supply two additional sizes of TB detection kits and also to significantly scale up TB kit production to satisfy projected needs.
For reference from an earlier update: "The technology used in the NanoLogix TB Test Kit is our BNP sandwiched-membrane technology. The use of the TB kit is to provide evidence of the presence of active (live) TB bacteria in a patient sample in 4-6 days rather than 3-5 weeks or more. The results from the NanoLogix TB tests are then processed through PCR (DNA testing) and other means to further define the identity of the TB. The original research paper citing the detection results and potential of pairing the NanoLogix technology with other technologies is available through this link:
https://www.omicsonline.org/1948-5948/JMBT-04-147.digital/JMBT-04-147.html
Related to this work, NanoLogix has received a request to pursue development of an N-Assay modified ELISA for detection and identification of TB. We will be doing so upon receipt of sufficient funding for that goal."
May 19, 2017
NanoLogix N-Assay Bacteria Diagnostic Technology for E. coli limited abstract
Novel Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of E. coli O157:H7
Novel Immunoassay for E coli O157:H7
Researchers: Classified until June 2017
Introduction: E. coli O157:H7 is associated with enterohemorrhagic infections, and is a concern for healthcare providers, food-handlers, and daycare providers. Rapid identification of this pathogen is critical in cases of outbreaks, and empirical treatment with broad-spectrum antibiotics may lead to more severe disease. We have developed an assay that allows for the simultaneous identification of E. coli O157:H7 and determination of its antibiotic susceptibility.
Methods: N-ASSAY
Methods Details Classified until June 2017
Results: O157:H7 was detected at and above 10^6 bacteria/ml following a 30-minute incubation, with no interference by other tested bacteria. By increasing the incubation time to 6 hours, the sensitivity of the test increased to 10^1 bacteria/ml. In addition, incubation with ceftriaxone during this six-hour time period showed inhibition of growth.
Summary: This assay allows for the rapid detection of a high inoculum of E. coli O157:H7, and sensitivity is increased following a six-hour incubation. Importantly, antibiotic susceptibility may be determined during this six-hour incubation.
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
May 8, 2017
Additional TB Test Kits ordered for Third World Gates Foundation Project
NanoLogix is pleased to announce that they have just (8 May 2017) received a new order for double the amount of their TB Diagnostic test kits delivered in April for use on a Third World research project funded by the National Institutes of Health, (NIH) the National Institute of Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation, with other funding from foreign Government agencies.
Since the request from the project representative stated that it is imperative the kits be delivered as soon as possible, NanoLogix is shipping the kits for Wednesday delivery. While the total sales amounts for the TB kits is in the thousands of dollars, Nanologix hopes the sales for use in this and other related TB projects will grow significantly.
The technology used in the NanoLogix TB Test Kit is our BNP sandwiched-membrane technology. The use of the TB kit is to provide evidence of the presence of active (live) TB bacteria in a patient sample in 4-6 days rather than 3-5 weeks or more. The results from the NanoLogix TB tests are then processed through PCR (DNA testing) and other means to further define the identity of the TB. The original research paper citing the detection results and potential of pairing the NanoLogix technology with other technologies is available through this link:
https://www.omicsonline.org/1948-5948/JMBT-04-147.digital/JMBT-04-147.html
Related to this work, NanoLogix has received a request to pursue development of an N-Assay modified ELISA for detection and identification of TB. We will be doing so upon receipt of sufficient funding for that goal.
In other news, patent work on either/both FlatPack and N-Assay patent applications has reached the stage where final examinations have been requested in Mexico, Canada, South Korea, and Brazil. Notification of FlatPack Patent Grant was received last week from Chile.
May 4, 2017
TB test Kits for use in Third World Gates Foundation Project
NanoLogix is pleased to elaborate further on an item of note from last month's announcement regarding shipment of TB Diagnostic kits to a Third World Research Project. The Company has sold and shipped their TB Diagnostic test kits for use on a Third World research project funded by the National Institutes of Health, (NIH) the National Institute of Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation, with other funding from foreign Government agencies.
Three reasons exist for this announcement. The first is to inform the public that whenever we released previous news where we were either named as being associated in research and development by an entity such as the US EPA or the University of Texas Health Science Center in Houston, or were cited in a research paper dealing with our technology by Battelle Biomedical Research Center in Ohio, those entities were all harassed by persons claiming to be NanoLogix shareholders who demanded to know the nature of the business relationships between the entities and NanoLogix and who asked for insider information regarding the status of the ongoing research. Those harassing efforts nearly destroyed the ongoing business relationships NanoLogix was truly privileged to have with those organizations. In this case anyone pursuing the same tact will come up against some very non-receptive forces.
The second is to demonstrate that we at NanoLogix had a goal, and that was to develop and provide to the world, diagnostic and research technologies that are premier and second to none, to create jobs in the rust belt area of northeast Ohio where the mindset of the area is steel mills, auto manufacturing, and low tech service jobs.
The third is to call attention to the facts that we, being a penny stock company, are considered the lowest of the low for investment. We are ignored by brokerages, especially ignored by the local media, and scorned by the investment community in general. Oddly enough, as ignored as we've been, we have still developed customized versions of our new N-Assay modified ELISA rapid bacteria diagnostic for one of the World's largest medical technology companies (under a very strong non-disclosure agreement), worked with the US EPA on developing tests for drinking and source waters, and had our technology presented as the fastest, most accurate and sensitive bacteria diagnostic test in the world. In addition, we've sold large numbers of proprietary packed FlatPacked petri plates in the USA and around the world for use in everything from simple quality control, food processing monitoring, soil testing, cosmetics and personal care products testing, environmental testing for post-flood contamination, water quality analysis, biodefense (we think, but classified), university research, and tens of thousands of users through Amazon and EBay for varied uses.
...and now we've sold TB diagnostics for use on a project funded by whom...?
Our share price and company are under attack by sick manipulators who only hurt dedicated shareholders. We as a company will survive and prosper.
We will expand our facilities as soon as feasible for increased FlatPack and N-Assay production, and are exploring relocating to a different state where we can be considered as bringing a benefit to the area.
Apr. 28, 2017
NanoLogix N-Assay Bacteria Diagnostic Technology for Rare Deinococcus Bacteria to be presented at AACC Annual Meeting in San Diego:
NanoLogix is pleased to announce that the N-Assay Bacteria Diagnostic, recently configured for detection and identification of a rare Deinococcus bacteria species will be presented in poster format at the American Association for Clinical Chemistry (AACC) 69th Annual Scientific Meeting and Clinical Lab Expo, to be held at the San Diego Convention Center in San Diego, California from July 30th through August 3rd, 2017. Dr. Jonathan Faro, MD, PhD and others associated with the development will be present for the poster session.
NanoLogix personnel are exploring the potential of staffing an exhibit booth at the event to display both the new modified-ELISA N-Assay diagnostic kit and also the FlatPack extended shelf life technology for petri plates.
The N-Assay Diagnostic furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus.
The published research results may be accessed through this link:
http://dx.doi.org/10.1155/2016/5293034
The AACC Deinococcus poster presentation illustrates how the N-Assay reduces the detection and identification times from roughly two weeks to a few days, with improved sensitivities over any other known test method.
Further information as to poster display and potential exhibit booth location will be made available in the near future when supplied to us by the AACC. Currently, general information for the event may be found by following this link:
https://www.aacc.org/meetings-and-events/2017-annual-meeting/clinical-lab-expo
The N-Assay Diagnostic for eColi will also be presented at the ASM Microbe 2017 in New Orleans June 1-5. Information for that event is available here:
https://www.asm.org/index.php/asm-microbe-2017
Apr. 4, 2017
NanoLogix has shipped TB test Kits for use in Third World Project
NanoLogix is pleased to announce items of note that have occurred this week. The first is that the Company has sold and shipped their TB Diagnostic test kits for use on a Third World research project funded by multiple US Federal and foreign Government agencies and a large international philanthropic organization. Once the project results are published we will be at liberty to elaborate further. The second item is that the Company today received the largest single delivery to date of petri plates for continued production of prepoured agar-filled FlatPacks, taking delivery of 150,000 sterilized petri plates.
Mar. 16, 2017
NanoLogix N-Assay Bacteria Diagnostic Technology for E. coli to be presented at June ASM Annual Meeting in New Orleans:
NanoLogix is pleased to announce that the N-Assay Bacteria Diagnostic, newly configured for E. coli will be presented in poster format at the American Society for Microbiology ASM Microbe 2017 to be held at the Ernest N. Morial Convention Center in New Orleans, Louisiana from June 1st through 5th. Dr. Sebastian Faro, MD, PhD and others associated with the development will be present for the poster session.
NanoLogix personnel are planning to staff an exhibit booth at the event to display both the Company-offered FlatPack for petri plates and the new N-Assay diagnostic. The FlatPack technology is becoming the premier petri plate storage method for those interested in long life room-temperature storage of prepared agar, with basic poured agars usable in as-new condition after 2-4 years of non-refrigerated storage. The NanoLogix FlatPack is available through www.nanologix.com and also on Amazon.com through two companies --- Evviva Scientific and Diamante Scientific.
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
Further information as to poster display and exhibit booth location will be made available in the near future when supplied to us by the ASM.
Mar. 2, 2017
NanoLogix is pleased to present a further update on the N-Assay Bacteria Diagnostic Technology:
After testing with customized N-Assay kits we supplied in January, the large medical technology client referenced in earlier updates has requested quotes from NanoLogix for expansion and further development using the N-Assay technology to detect additional bacteria species and genera.
Nanologix personnel and associates are excited to work with one of the World's largest medical companies on these N-Assay customizations. Due to a confidentiality agreement with our client, we cannot currently disclose the client identity.
There still remains the step of an independent time and sensitivity study for NanoLogix prior to marketing and sales for clinical use of the N-Assay. Personnel at a number of hospitals are reviewing potential study participation.
Jan. 9, 2017
NanoLogix is pleased to present a brief update on the N-Assay Bacteria Diagnostic Technology:
The N-Assay takes its place on our FDA medical device listing:
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm?lid=469637&lpcd=LIB
There is the remaining step of an independent time and sensitivity study for NanoLogix prior to marketing and sales for clinical use of the N-Assay.
NanoLogix has supplied all of the initially contracted and customized N-Assay kits to our multi-billion dollar medical technology client and we are awaiting results of their global testing.
Dec. 20, 2016
NanoLogix is pleased to announce the following Update:
The Company has narrowed its selection of buildings to use as a larger production facility in northeast Ohio. Two existing buildings are now under consideration to house NanoLogix production for both petri plates and for production of the new N-Assay ELISA-based rapid bacteria diagnostic. The projected expenditure for establishing N-Assay production and increasing petri plate production is roughly $900,000 for production equipment, $125,000 for the construction of two separate 70' X 30' production cleanrooms, and $40,000 for additional equipment such as forklifts.
This expansion is projected to result in market share increase for petri plate sales due to markedly improved economies of scale, and position NanoLogix with a significant production capability for the new N-Assay modified ELISA comprehensive bacteria diagnostic kit. The Company expects the expansion will result in ten additional jobs starting with the delivery and setup of the production equipment in 2017 and another ten positions upon expansion of N-Assay sales.
Over the coming six months we expect to finance the expansion through a combination of increasing revenue from sales of both product lines and fundraising through our current SEC Regulation D, Rule 506 offering for private placement sales of shares.
Any share issuance financing for this expansion is being structured primarily, but not solely, through a series of equity tranches and stock warrants. Using this method, the Company hopes to keep stock dilution to a minimum and will proceed with the interests of the shareholders in mind, including extending the timeline for expansion as necessary if equity costs are not favorable to NanoLogix.
The Company is preparing to seek licensees in Europe and Hong Kong for production of FlatPack Petri Plates under the recent EU FlatPack patent approval.
In response to queries coming to our office regarding our customization of the N-Assay for a multibillion medical technology company: we have sold 600+ of the N-Assay to them and will be supplying more in addition to further customization for other bacteria in 2017. As our arrangement with the client is CONFIDENTIAL, we will not be releasing their name.
Merry Christmas from Carol, Debby, Kim, Travis, Bret and all
Dec. 6, 2016
NanoLogix is pleased to announce the following Update:
The Company is currently searching for a larger production facility in northeast Ohio. In the past three weeks NanoLogix management and production staff have viewed, toured, and measured four separate sites to ascertain site suitability for relocating and expanding NanoLogix production for both petri plates and for production of the new N-Assay ELISA-based rapid bacteria diagnostic.
The new sites being surveyed range from 10,000 square feet to 22,000 square feet, three to seven times the size of our current facility. All sites viewed offer additional square footage for further expansion as required.
NanoLogix is also in the process of specifying and ordering new equipment for the production of both petri plates and the new N-Assay.
The two petri plate filling machines that have been configured for order are both OnlineEngineering MultiDish Model 968 with ancillary equipment. The Model 968 is capable of filling 9,600 plates per hour, so the two machines should be capable of meeting production needs for the forseeable future. Further information on the equipment can be found at: www.online-engineering.com
The N-Assay equipment currently being researched and specified are automatic pippetting machines for application of antibodies, etc., to the ELISA plates used for this revolutionary rapid bacteria diagnostic technology.
The two technologies will be housed in separate modular cleanrooms in order to comply with specific FDA requirements for manufacturing of each product.
The projected timeline for delivery and assembly of modular cleanrooms, the OnlineEngineering equipment, and the automated pippetting machines is sometime in the second quarter of 2017, while configuration of whichever of the candidate sites is chosen is projected to begin in the first quarter of 2017.
Petri plate production is currently in Hubbard, Ohio, while N-Assay production is in Houston, Texas. N-Assay production in Ohio is projected to begin in the second quarter of 2017.
------------------------------------------------------------------------------------------------------------------------------
Updates are available by signing up for eNews on the company's homepage at nanologix.com.
Company Updates
June 8, 2017
EU & Hong Kong FlatPack Patent Issued
NanoLogix is extremely pleased to announce the patent issuance on 7 June 2017 in the EU and Hong Kong for their unique and exclusively licensed petri plate plate packaging system known as the FlatPack. The FlatPack, a method of vacuum-packing of petri plates in an inert gas environment, enables long term storage of many types of petri plates at room temperature for two years or more without deterioration of the nutrient agar contained in the filled plates. Standard storage times and conditions for competitors' petri plates are normally three months in a refrigerated environment. The potential economic impact of long term high quality non-refrigerated agar-filled petri plates is significant, with daily use of agar-filled petri plates worldwide numbering in the millions and access to both guaranteed-quality agar plates and dependable refrigeration for storage varying widely from area to area.
A PDF of the issued patent may be viewed here:
http://www.freepatentsonline.com/EP2699491.pdf
A research paper by a renowned Biomedical Research Center on the qualities of FlatPacked petri plates in a comparison test with competitors can be accessed here:
http://medcraveonline.com/JMEN/JMEN-03-00075.pdf
NanoLogix' intention is to register and validate the patent in most of the 40 EU member nations and patent treaty affiliates in addition to Hong Kong. Following that process, NanoLogix intends to seek licencee(s) for manufacturing and marketing for the those areas.
For reference: The patent process from the date of filing to issuance took five years and two months
June 5, 2017
Reception of the NanoLogix N-Assay Bacteria Diagnostic Technology Poster for E. coli Presented at the American Society for Microbiology (ASM Microbe) Annual meeting
Novel Rapid Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of E. coli O157:H7
Jonathan Faro, MD, PhD and Sebastian Faro, MD, PhD, medical researchers presenting the technology poster at the ASM Annual meeting in New Orleans this past weekend stated:
"ASM Microbe was a very stimulating meeting. We enjoyed meeting many investigators and the engaging discussions that followed. Of the many rapid ID tests either on the market or the many more that presented and will soon be available, our assay is the most unique, and has the ability to provide the greatest limit of detection while simultaneously determining antibiotic susceptibility."
Further information from NanoLogix metrics monitoring indicated interest from at least two major laboratories.
The N-Assay is currently undergoing development for rapid detection of Urinary Tract Infections (UTI) and we anticipate the N-Assay to be debuted soon as the definitive UTI test for speed, accuracy, and sensitivity.
Two published examples of the N-Assay and its performance can be accessed through the following links:
https://www.hindawi.com/journals/idog/2016/5293034/
http://nanologix.com/news/poster-e-coli-0157.pdf
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B
Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
June 2, 2017
Update: NanoLogix N-Assay Bacteria Diagnostic Technology Poster for E. coli To Be Presented Tomorrow at the American Society for Microbiology (ASM) in New Orleans
Novel Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of E. coli O157:H7
This poster presentation will occur Saturday, June 3rd from 12:15 to 14:15 at position #456 in the category of Diagnostic Bacteriology III.
http://nanologix.com/news/poster-e-coli-0157.pdf
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
June 1, 2017
NanoLogix TB Detection Technology Use on Africa Project Increases
NanoLogix is pleased to announce that this week they shipped a new order for their TB Diagnostic test kits for use on an Africa research project funded by the National Institutes of Health, (NIH) the National Institute of Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation, with other funding from US and foreign Government agencies.
This is the third order since April on the Africa Project. NanoLogix was informed that in addition to the two sizes of kits sold in this order (150 mm and 100 mm), NanoLogix should prepare to supply two additional sizes of TB detection kits and also to significantly scale up TB kit production to satisfy projected needs.
For reference from an earlier update: "The technology used in the NanoLogix TB Test Kit is our BNP sandwiched-membrane technology. The use of the TB kit is to provide evidence of the presence of active (live) TB bacteria in a patient sample in 4-6 days rather than 3-5 weeks or more. The results from the NanoLogix TB tests are then processed through PCR (DNA testing) and other means to further define the identity of the TB. The original research paper citing the detection results and potential of pairing the NanoLogix technology with other technologies is available through this link:
https://www.omicsonline.org/1948-5948/JMBT-04-147.digital/JMBT-04-147.html
Related to this work, NanoLogix has received a request to pursue development of an N-Assay modified ELISA for detection and identification of TB. We will be doing so upon receipt of sufficient funding for that goal."
May 19, 2017
NanoLogix N-Assay Bacteria Diagnostic Technology for E. coli limited abstract
Novel Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of E. coli O157:H7
Novel Immunoassay for E coli O157:H7
Researchers: Classified until June 2017
Introduction: E. coli O157:H7 is associated with enterohemorrhagic infections, and is a concern for healthcare providers, food-handlers, and daycare providers. Rapid identification of this pathogen is critical in cases of outbreaks, and empirical treatment with broad-spectrum antibiotics may lead to more severe disease. We have developed an assay that allows for the simultaneous identification of E. coli O157:H7 and determination of its antibiotic susceptibility.
Methods: N-ASSAY
Methods Details Classified until June 2017
Results: O157:H7 was detected at and above 10^6 bacteria/ml following a 30-minute incubation, with no interference by other tested bacteria. By increasing the incubation time to 6 hours, the sensitivity of the test increased to 10^1 bacteria/ml. In addition, incubation with ceftriaxone during this six-hour time period showed inhibition of growth.
Summary: This assay allows for the rapid detection of a high inoculum of E. coli O157:H7, and sensitivity is increased following a six-hour incubation. Importantly, antibiotic susceptibility may be determined during this six-hour incubation.
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
May 8, 2017
Additional TB Test Kits ordered for Third World Gates Foundation Project
NanoLogix is pleased to announce that they have just (8 May 2017) received a new order for double the amount of their TB Diagnostic test kits delivered in April for use on a Third World research project funded by the National Institutes of Health, (NIH) the National Institute of Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation, with other funding from foreign Government agencies.
Since the request from the project representative stated that it is imperative the kits be delivered as soon as possible, NanoLogix is shipping the kits for Wednesday delivery. While the total sales amounts for the TB kits is in the thousands of dollars, Nanologix hopes the sales for use in this and other related TB projects will grow significantly.
The technology used in the NanoLogix TB Test Kit is our BNP sandwiched-membrane technology. The use of the TB kit is to provide evidence of the presence of active (live) TB bacteria in a patient sample in 4-6 days rather than 3-5 weeks or more. The results from the NanoLogix TB tests are then processed through PCR (DNA testing) and other means to further define the identity of the TB. The original research paper citing the detection results and potential of pairing the NanoLogix technology with other technologies is available through this link:
https://www.omicsonline.org/1948-5948/JMBT-04-147.digital/JMBT-04-147.html
Related to this work, NanoLogix has received a request to pursue development of an N-Assay modified ELISA for detection and identification of TB. We will be doing so upon receipt of sufficient funding for that goal.
In other news, patent work on either/both FlatPack and N-Assay patent applications has reached the stage where final examinations have been requested in Mexico, Canada, South Korea, and Brazil. Notification of FlatPack Patent Grant was received last week from Chile.
May 4, 2017
TB test Kits for use in Third World Gates Foundation Project
NanoLogix is pleased to elaborate further on an item of note from last month's announcement regarding shipment of TB Diagnostic kits to a Third World Research Project. The Company has sold and shipped their TB Diagnostic test kits for use on a Third World research project funded by the National Institutes of Health, (NIH) the National Institute of Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation, with other funding from foreign Government agencies.
Three reasons exist for this announcement. The first is to inform the public that whenever we released previous news where we were either named as being associated in research and development by an entity such as the US EPA or the University of Texas Health Science Center in Houston, or were cited in a research paper dealing with our technology by Battelle Biomedical Research Center in Ohio, those entities were all harassed by persons claiming to be NanoLogix shareholders who demanded to know the nature of the business relationships between the entities and NanoLogix and who asked for insider information regarding the status of the ongoing research. Those harassing efforts nearly destroyed the ongoing business relationships NanoLogix was truly privileged to have with those organizations. In this case anyone pursuing the same tact will come up against some very non-receptive forces.
The second is to demonstrate that we at NanoLogix had a goal, and that was to develop and provide to the world, diagnostic and research technologies that are premier and second to none, to create jobs in the rust belt area of northeast Ohio where the mindset of the area is steel mills, auto manufacturing, and low tech service jobs.
The third is to call attention to the facts that we, being a penny stock company, are considered the lowest of the low for investment. We are ignored by brokerages, especially ignored by the local media, and scorned by the investment community in general. Oddly enough, as ignored as we've been, we have still developed customized versions of our new N-Assay modified ELISA rapid bacteria diagnostic for one of the World's largest medical technology companies (under a very strong non-disclosure agreement), worked with the US EPA on developing tests for drinking and source waters, and had our technology presented as the fastest, most accurate and sensitive bacteria diagnostic test in the world. In addition, we've sold large numbers of proprietary packed FlatPacked petri plates in the USA and around the world for use in everything from simple quality control, food processing monitoring, soil testing, cosmetics and personal care products testing, environmental testing for post-flood contamination, water quality analysis, biodefense (we think, but classified), university research, and tens of thousands of users through Amazon and EBay for varied uses.
...and now we've sold TB diagnostics for use on a project funded by whom...?
Our share price and company are under attack by sick manipulators who only hurt dedicated shareholders. We as a company will survive and prosper.
We will expand our facilities as soon as feasible for increased FlatPack and N-Assay production, and are exploring relocating to a different state where we can be considered as bringing a benefit to the area.
Apr. 28, 2017
NanoLogix N-Assay Bacteria Diagnostic Technology for Rare Deinococcus Bacteria to be presented at AACC Annual Meeting in San Diego:
NanoLogix is pleased to announce that the N-Assay Bacteria Diagnostic, recently configured for detection and identification of a rare Deinococcus bacteria species will be presented in poster format at the American Association for Clinical Chemistry (AACC) 69th Annual Scientific Meeting and Clinical Lab Expo, to be held at the San Diego Convention Center in San Diego, California from July 30th through August 3rd, 2017. Dr. Jonathan Faro, MD, PhD and others associated with the development will be present for the poster session.
NanoLogix personnel are exploring the potential of staffing an exhibit booth at the event to display both the new modified-ELISA N-Assay diagnostic kit and also the FlatPack extended shelf life technology for petri plates.
The N-Assay Diagnostic furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus.
The published research results may be accessed through this link:
http://dx.doi.org/10.1155/2016/5293034
The AACC Deinococcus poster presentation illustrates how the N-Assay reduces the detection and identification times from roughly two weeks to a few days, with improved sensitivities over any other known test method.
Further information as to poster display and potential exhibit booth location will be made available in the near future when supplied to us by the AACC. Currently, general information for the event may be found by following this link:
https://www.aacc.org/meetings-and-events/2017-annual-meeting/clinical-lab-expo
The N-Assay Diagnostic for eColi will also be presented at the ASM Microbe 2017 in New Orleans June 1-5. Information for that event is available here:
https://www.asm.org/index.php/asm-microbe-2017
Apr. 4, 2017
NanoLogix has shipped TB test Kits for use in Third World Project
NanoLogix is pleased to announce items of note that have occurred this week. The first is that the Company has sold and shipped their TB Diagnostic test kits for use on a Third World research project funded by multiple US Federal and foreign Government agencies and a large international philanthropic organization. Once the project results are published we will be at liberty to elaborate further. The second item is that the Company today received the largest single delivery to date of petri plates for continued production of prepoured agar-filled FlatPacks, taking delivery of 150,000 sterilized petri plates.
Mar. 16, 2017
NanoLogix N-Assay Bacteria Diagnostic Technology for E. coli to be presented at June ASM Annual Meeting in New Orleans:
NanoLogix is pleased to announce that the N-Assay Bacteria Diagnostic, newly configured for E. coli will be presented in poster format at the American Society for Microbiology ASM Microbe 2017 to be held at the Ernest N. Morial Convention Center in New Orleans, Louisiana from June 1st through 5th. Dr. Sebastian Faro, MD, PhD and others associated with the development will be present for the poster session.
NanoLogix personnel are planning to staff an exhibit booth at the event to display both the Company-offered FlatPack for petri plates and the new N-Assay diagnostic. The FlatPack technology is becoming the premier petri plate storage method for those interested in long life room-temperature storage of prepared agar, with basic poured agars usable in as-new condition after 2-4 years of non-refrigerated storage. The NanoLogix FlatPack is available through www.nanologix.com and also on Amazon.com through two companies --- Evviva Scientific and Diamante Scientific.
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
Further information as to poster display and exhibit booth location will be made available in the near future when supplied to us by the ASM.
Mar. 2, 2017
NanoLogix is pleased to present a further update on the N-Assay Bacteria Diagnostic Technology:
After testing with customized N-Assay kits we supplied in January, the large medical technology client referenced in earlier updates has requested quotes from NanoLogix for expansion and further development using the N-Assay technology to detect additional bacteria species and genera.
Nanologix personnel and associates are excited to work with one of the World's largest medical companies on these N-Assay customizations. Due to a confidentiality agreement with our client, we cannot currently disclose the client identity.
There still remains the step of an independent time and sensitivity study for NanoLogix prior to marketing and sales for clinical use of the N-Assay. Personnel at a number of hospitals are reviewing potential study participation.
Jan. 9, 2017
NanoLogix is pleased to present a brief update on the N-Assay Bacteria Diagnostic Technology:
The N-Assay takes its place on our FDA medical device listing:
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm?lid=469637&lpcd=LIB
There is the remaining step of an independent time and sensitivity study for NanoLogix prior to marketing and sales for clinical use of the N-Assay.
NanoLogix has supplied all of the initially contracted and customized N-Assay kits to our multi-billion dollar medical technology client and we are awaiting results of their global testing.
Dec. 20, 2016
NanoLogix is pleased to announce the following Update:
The Company has narrowed its selection of buildings to use as a larger production facility in northeast Ohio. Two existing buildings are now under consideration to house NanoLogix production for both petri plates and for production of the new N-Assay ELISA-based rapid bacteria diagnostic. The projected expenditure for establishing N-Assay production and increasing petri plate production is roughly $900,000 for production equipment, $125,000 for the construction of two separate 70' X 30' production cleanrooms, and $40,000 for additional equipment such as forklifts.
This expansion is projected to result in market share increase for petri plate sales due to markedly improved economies of scale, and position NanoLogix with a significant production capability for the new N-Assay modified ELISA comprehensive bacteria diagnostic kit. The Company expects the expansion will result in ten additional jobs starting with the delivery and setup of the production equipment in 2017 and another ten positions upon expansion of N-Assay sales.
Over the coming six months we expect to finance the expansion through a combination of increasing revenue from sales of both product lines and fundraising through our current SEC Regulation D, Rule 506 offering for private placement sales of shares.
Any share issuance financing for this expansion is being structured primarily, but not solely, through a series of equity tranches and stock warrants. Using this method, the Company hopes to keep stock dilution to a minimum and will proceed with the interests of the shareholders in mind, including extending the timeline for expansion as necessary if equity costs are not favorable to NanoLogix.
The Company is preparing to seek licensees in Europe and Hong Kong for production of FlatPack Petri Plates under the recent EU FlatPack patent approval.
In response to queries coming to our office regarding our customization of the N-Assay for a multibillion medical technology company: we have sold 600+ of the N-Assay to them and will be supplying more in addition to further customization for other bacteria in 2017. As our arrangement with the client is CONFIDENTIAL, we will not be releasing their name.
Merry Christmas from Carol, Debby, Kim, Travis, Bret and all
Dec. 6, 2016
NanoLogix is pleased to announce the following Update:
The Company is currently searching for a larger production facility in northeast Ohio. In the past three weeks NanoLogix management and production staff have viewed, toured, and measured four separate sites to ascertain site suitability for relocating and expanding NanoLogix production for both petri plates and for production of the new N-Assay ELISA-based rapid bacteria diagnostic.
The new sites being surveyed range from 10,000 square feet to 22,000 square feet, three to seven times the size of our current facility. All sites viewed offer additional square footage for further expansion as required.
NanoLogix is also in the process of specifying and ordering new equipment for the production of both petri plates and the new N-Assay.
The two petri plate filling machines that have been configured for order are both OnlineEngineering MultiDish Model 968 with ancillary equipment. The Model 968 is capable of filling 9,600 plates per hour, so the two machines should be capable of meeting production needs for the forseeable future. Further information on the equipment can be found at: www.online-engineering.com
The N-Assay equipment currently being researched and specified are automatic pippetting machines for application of antibodies, etc., to the ELISA plates used for this revolutionary rapid bacteria diagnostic technology.
The two technologies will be housed in separate modular cleanrooms in order to comply with specific FDA requirements for manufacturing of each product.
The projected timeline for delivery and assembly of modular cleanrooms, the OnlineEngineering equipment, and the automated pippetting machines is sometime in the second quarter of 2017, while configuration of whichever of the candidate sites is chosen is projected to begin in the first quarter of 2017.
Petri plate production is currently in Hubbard, Ohio, while N-Assay production is in Houston, Texas. N-Assay production in Ohio is projected to begin in the second quarter of 2017.
------------------------------------------------------------------------------------------------------------------------------
Updates are available by signing up for eNews on the company's homepage at nanologix.com.
Company Updates
June 5, 2017
Reception of the NanoLogix N-Assay Bacteria Diagnostic Technology Poster for E. coli Presented at the American Society for Microbiology (ASM Microbe) Annual meeting
Novel Rapid Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of E. coli O157:H7
Jonathan Faro, MD, PhD and Sebastian Faro, MD, PhD, medical researchers presenting the technology poster at the ASM Annual meeting in New Orleans this past weekend stated:
"ASM Microbe was a very stimulating meeting. We enjoyed meeting many investigators and the engaging discussions that followed. Of the many rapid ID tests either on the market or the many more that presented and will soon be available, our assay is the most unique, and has the ability to provide the greatest limit of detection while simultaneously determining antibiotic susceptibility."
Further information from NanoLogix metrics monitoring indicated interest from at least two major laboratories.
The N-Assay is currently undergoing development for rapid detection of Urinary Tract Infections (UTI) and we anticipate the N-Assay to be debuted soon as the definitive UTI test for speed, accuracy, and sensitivity.
Two published examples of the N-Assay and its performance can be accessed through the following links:
https://www.hindawi.com/journals/idog/2016/5293034/
http://nanologix.com/news/poster-e-coli-0157.pdf
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B
Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
June 2, 2017
Update: NanoLogix N-Assay Bacteria Diagnostic Technology Poster for E. coli To Be Presented Tomorrow at the American Society for Microbiology (ASM) in New Orleans
Novel Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of E. coli O157:H7
This poster presentation will occur Saturday, June 3rd from 12:15 to 14:15 at position #456 in the category of Diagnostic Bacteriology III.
http://nanologix.com/news/poster-e-coli-0157.pdf
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
June 1, 2017
NanoLogix TB Detection Technology Use on Africa Project Increases
NanoLogix is pleased to announce that this week they shipped a new order for their TB Diagnostic test kits for use on an Africa research project funded by the National Institutes of Health, (NIH) the National Institute of Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation, with other funding from US and foreign Government agencies.
This is the third order since April on the Africa Project. NanoLogix was informed that in addition to the two sizes of kits sold in this order (150 mm and 100 mm), NanoLogix should prepare to supply two additional sizes of TB detection kits and also to significantly scale up TB kit production to satisfy projected needs.
For reference from an earlier update: "The technology used in the NanoLogix TB Test Kit is our BNP sandwiched-membrane technology. The use of the TB kit is to provide evidence of the presence of active (live) TB bacteria in a patient sample in 4-6 days rather than 3-5 weeks or more. The results from the NanoLogix TB tests are then processed through PCR (DNA testing) and other means to further define the identity of the TB. The original research paper citing the detection results and potential of pairing the NanoLogix technology with other technologies is available through this link:
https://www.omicsonline.org/1948-5948/JMBT-04-147.digital/JMBT-04-147.html
Related to this work, NanoLogix has received a request to pursue development of an N-Assay modified ELISA for detection and identification of TB. We will be doing so upon receipt of sufficient funding for that goal."
May 19, 2017
NanoLogix N-Assay Bacteria Diagnostic Technology for E. coli limited abstract
Novel Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of E. coli O157:H7
Novel Immunoassay for E coli O157:H7
Researchers: Classified until June 2017
Introduction: E. coli O157:H7 is associated with enterohemorrhagic infections, and is a concern for healthcare providers, food-handlers, and daycare providers. Rapid identification of this pathogen is critical in cases of outbreaks, and empirical treatment with broad-spectrum antibiotics may lead to more severe disease. We have developed an assay that allows for the simultaneous identification of E. coli O157:H7 and determination of its antibiotic susceptibility.
Methods: N-ASSAY
Methods Details Classified until June 2017
Results: O157:H7 was detected at and above 10^6 bacteria/ml following a 30-minute incubation, with no interference by other tested bacteria. By increasing the incubation time to 6 hours, the sensitivity of the test increased to 10^1 bacteria/ml. In addition, incubation with ceftriaxone during this six-hour time period showed inhibition of growth.
Summary: This assay allows for the rapid detection of a high inoculum of E. coli O157:H7, and sensitivity is increased following a six-hour incubation. Importantly, antibiotic susceptibility may be determined during this six-hour incubation.
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
May 8, 2017
Additional TB Test Kits ordered for Third World Gates Foundation Project
NanoLogix is pleased to announce that they have just (8 May 2017) received a new order for double the amount of their TB Diagnostic test kits delivered in April for use on a Third World research project funded by the National Institutes of Health, (NIH) the National Institute of Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation, with other funding from foreign Government agencies.
Since the request from the project representative stated that it is imperative the kits be delivered as soon as possible, NanoLogix is shipping the kits for Wednesday delivery. While the total sales amounts for the TB kits is in the thousands of dollars, Nanologix hopes the sales for use in this and other related TB projects will grow significantly.
The technology used in the NanoLogix TB Test Kit is our BNP sandwiched-membrane technology. The use of the TB kit is to provide evidence of the presence of active (live) TB bacteria in a patient sample in 4-6 days rather than 3-5 weeks or more. The results from the NanoLogix TB tests are then processed through PCR (DNA testing) and other means to further define the identity of the TB. The original research paper citing the detection results and potential of pairing the NanoLogix technology with other technologies is available through this link:
https://www.omicsonline.org/1948-5948/JMBT-04-147.digital/JMBT-04-147.html
Related to this work, NanoLogix has received a request to pursue development of an N-Assay modified ELISA for detection and identification of TB. We will be doing so upon receipt of sufficient funding for that goal.
In other news, patent work on either/both FlatPack and N-Assay patent applications has reached the stage where final examinations have been requested in Mexico, Canada, South Korea, and Brazil. Notification of FlatPack Patent Grant was received last week from Chile.
May 4, 2017
TB test Kits for use in Third World Gates Foundation Project
NanoLogix is pleased to elaborate further on an item of note from last month's announcement regarding shipment of TB Diagnostic kits to a Third World Research Project. The Company has sold and shipped their TB Diagnostic test kits for use on a Third World research project funded by the National Institutes of Health, (NIH) the National Institute of Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation, with other funding from foreign Government agencies.
Three reasons exist for this announcement. The first is to inform the public that whenever we released previous news where we were either named as being associated in research and development by an entity such as the US EPA or the University of Texas Health Science Center in Houston, or were cited in a research paper dealing with our technology by Battelle Biomedical Research Center in Ohio, those entities were all harassed by persons claiming to be NanoLogix shareholders who demanded to know the nature of the business relationships between the entities and NanoLogix and who asked for insider information regarding the status of the ongoing research. Those harassing efforts nearly destroyed the ongoing business relationships NanoLogix was truly privileged to have with those organizations. In this case anyone pursuing the same tact will come up against some very non-receptive forces.
The second is to demonstrate that we at NanoLogix had a goal, and that was to develop and provide to the world, diagnostic and research technologies that are premier and second to none, to create jobs in the rust belt area of northeast Ohio where the mindset of the area is steel mills, auto manufacturing, and low tech service jobs.
The third is to call attention to the facts that we, being a penny stock company, are considered the lowest of the low for investment. We are ignored by brokerages, especially ignored by the local media, and scorned by the investment community in general. Oddly enough, as ignored as we've been, we have still developed customized versions of our new N-Assay modified ELISA rapid bacteria diagnostic for one of the World's largest medical technology companies (under a very strong non-disclosure agreement), worked with the US EPA on developing tests for drinking and source waters, and had our technology presented as the fastest, most accurate and sensitive bacteria diagnostic test in the world. In addition, we've sold large numbers of proprietary packed FlatPacked petri plates in the USA and around the world for use in everything from simple quality control, food processing monitoring, soil testing, cosmetics and personal care products testing, environmental testing for post-flood contamination, water quality analysis, biodefense (we think, but classified), university research, and tens of thousands of users through Amazon and EBay for varied uses.
...and now we've sold TB diagnostics for use on a project funded by whom...?
Our share price and company are under attack by sick manipulators who only hurt dedicated shareholders. We as a company will survive and prosper.
We will expand our facilities as soon as feasible for increased FlatPack and N-Assay production, and are exploring relocating to a different state where we can be considered as bringing a benefit to the area.
Apr. 28, 2017
NanoLogix N-Assay Bacteria Diagnostic Technology for Rare Deinococcus Bacteria to be presented at AACC Annual Meeting in San Diego:
NanoLogix is pleased to announce that the N-Assay Bacteria Diagnostic, recently configured for detection and identification of a rare Deinococcus bacteria species will be presented in poster format at the American Association for Clinical Chemistry (AACC) 69th Annual Scientific Meeting and Clinical Lab Expo, to be held at the San Diego Convention Center in San Diego, California from July 30th through August 3rd, 2017. Dr. Jonathan Faro, MD, PhD and others associated with the development will be present for the poster session.
NanoLogix personnel are exploring the potential of staffing an exhibit booth at the event to display both the new modified-ELISA N-Assay diagnostic kit and also the FlatPack extended shelf life technology for petri plates.
The N-Assay Diagnostic furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus.
The published research results may be accessed through this link:
http://dx.doi.org/10.1155/2016/5293034
The AACC Deinococcus poster presentation illustrates how the N-Assay reduces the detection and identification times from roughly two weeks to a few days, with improved sensitivities over any other known test method.
Further information as to poster display and potential exhibit booth location will be made available in the near future when supplied to us by the AACC. Currently, general information for the event may be found by following this link:
https://www.aacc.org/meetings-and-events/2017-annual-meeting/clinical-lab-expo
The N-Assay Diagnostic for eColi will also be presented at the ASM Microbe 2017 in New Orleans June 1-5. Information for that event is available here:
https://www.asm.org/index.php/asm-microbe-2017
Apr. 4, 2017
NanoLogix has shipped TB test Kits for use in Third World Project
NanoLogix is pleased to announce items of note that have occurred this week. The first is that the Company has sold and shipped their TB Diagnostic test kits for use on a Third World research project funded by multiple US Federal and foreign Government agencies and a large international philanthropic organization. Once the project results are published we will be at liberty to elaborate further. The second item is that the Company today received the largest single delivery to date of petri plates for continued production of prepoured agar-filled FlatPacks, taking delivery of 150,000 sterilized petri plates.
Mar. 16, 2017
NanoLogix N-Assay Bacteria Diagnostic Technology for E. coli to be presented at June ASM Annual Meeting in New Orleans:
NanoLogix is pleased to announce that the N-Assay Bacteria Diagnostic, newly configured for E. coli will be presented in poster format at the American Society for Microbiology ASM Microbe 2017 to be held at the Ernest N. Morial Convention Center in New Orleans, Louisiana from June 1st through 5th. Dr. Sebastian Faro, MD, PhD and others associated with the development will be present for the poster session.
NanoLogix personnel are planning to staff an exhibit booth at the event to display both the Company-offered FlatPack for petri plates and the new N-Assay diagnostic. The FlatPack technology is becoming the premier petri plate storage method for those interested in long life room-temperature storage of prepared agar, with basic poured agars usable in as-new condition after 2-4 years of non-refrigerated storage. The NanoLogix FlatPack is available through www.nanologix.com and also on Amazon.com through two companies --- Evviva Scientific and Diamante Scientific.
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
Further information as to poster display and exhibit booth location will be made available in the near future when supplied to us by the ASM.
Mar. 2, 2017
NanoLogix is pleased to present a further update on the N-Assay Bacteria Diagnostic Technology:
After testing with customized N-Assay kits we supplied in January, the large medical technology client referenced in earlier updates has requested quotes from NanoLogix for expansion and further development using the N-Assay technology to detect additional bacteria species and genera.
Nanologix personnel and associates are excited to work with one of the World's largest medical companies on these N-Assay customizations. Due to a confidentiality agreement with our client, we cannot currently disclose the client identity.
There still remains the step of an independent time and sensitivity study for NanoLogix prior to marketing and sales for clinical use of the N-Assay. Personnel at a number of hospitals are reviewing potential study participation.
Jan. 9, 2017
NanoLogix is pleased to present a brief update on the N-Assay Bacteria Diagnostic Technology:
The N-Assay takes its place on our FDA medical device listing:
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm?lid=469637&lpcd=LIB
There is the remaining step of an independent time and sensitivity study for NanoLogix prior to marketing and sales for clinical use of the N-Assay.
NanoLogix has supplied all of the initially contracted and customized N-Assay kits to our multi-billion dollar medical technology client and we are awaiting results of their global testing.
Dec. 20, 2016
NanoLogix is pleased to announce the following Update:
The Company has narrowed its selection of buildings to use as a larger production facility in northeast Ohio. Two existing buildings are now under consideration to house NanoLogix production for both petri plates and for production of the new N-Assay ELISA-based rapid bacteria diagnostic. The projected expenditure for establishing N-Assay production and increasing petri plate production is roughly $900,000 for production equipment, $125,000 for the construction of two separate 70' X 30' production cleanrooms, and $40,000 for additional equipment such as forklifts.
This expansion is projected to result in market share increase for petri plate sales due to markedly improved economies of scale, and position NanoLogix with a significant production capability for the new N-Assay modified ELISA comprehensive bacteria diagnostic kit. The Company expects the expansion will result in ten additional jobs starting with the delivery and setup of the production equipment in 2017 and another ten positions upon expansion of N-Assay sales.
Over the coming six months we expect to finance the expansion through a combination of increasing revenue from sales of both product lines and fundraising through our current SEC Regulation D, Rule 506 offering for private placement sales of shares.
Any share issuance financing for this expansion is being structured primarily, but not solely, through a series of equity tranches and stock warrants. Using this method, the Company hopes to keep stock dilution to a minimum and will proceed with the interests of the shareholders in mind, including extending the timeline for expansion as necessary if equity costs are not favorable to NanoLogix.
The Company is preparing to seek licensees in Europe and Hong Kong for production of FlatPack Petri Plates under the recent EU FlatPack patent approval.
In response to queries coming to our office regarding our customization of the N-Assay for a multibillion medical technology company: we have sold 600+ of the N-Assay to them and will be supplying more in addition to further customization for other bacteria in 2017. As our arrangement with the client is CONFIDENTIAL, we will not be releasing their name.
Merry Christmas from Carol, Debby, Kim, Travis, Bret and all
Dec. 6, 2016
NanoLogix is pleased to announce the following Update:
The Company is currently searching for a larger production facility in northeast Ohio. In the past three weeks NanoLogix management and production staff have viewed, toured, and measured four separate sites to ascertain site suitability for relocating and expanding NanoLogix production for both petri plates and for production of the new N-Assay ELISA-based rapid bacteria diagnostic.
The new sites being surveyed range from 10,000 square feet to 22,000 square feet, three to seven times the size of our current facility. All sites viewed offer additional square footage for further expansion as required.
NanoLogix is also in the process of specifying and ordering new equipment for the production of both petri plates and the new N-Assay.
The two petri plate filling machines that have been configured for order are both OnlineEngineering MultiDish Model 968 with ancillary equipment. The Model 968 is capable of filling 9,600 plates per hour, so the two machines should be capable of meeting production needs for the forseeable future. Further information on the equipment can be found at: www.online-engineering.com
The N-Assay equipment currently being researched and specified are automatic pippetting machines for application of antibodies, etc., to the ELISA plates used for this revolutionary rapid bacteria diagnostic technology.
The two technologies will be housed in separate modular cleanrooms in order to comply with specific FDA requirements for manufacturing of each product.
The projected timeline for delivery and assembly of modular cleanrooms, the OnlineEngineering equipment, and the automated pippetting machines is sometime in the second quarter of 2017, while configuration of whichever of the candidate sites is chosen is projected to begin in the first quarter of 2017.
Petri plate production is currently in Hubbard, Ohio, while N-Assay production is in Houston, Texas. N-Assay production in Ohio is projected to begin in the second quarter of 2017.
------------------------------------------------------------------------------------------------------------------------------
Updates are available by signing up for eNews on the company's homepage at nanologix.com.
Company Updates
June 2, 2017
Update: NanoLogix N-Assay Bacteria Diagnostic Technology Poster for E. coli To Be Presented Tomorrow at the American Society for Microbiology (ASM) in New Orleans
Novel Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of E. coli O157:H7
This poster presentation will occur Saturday, June 3rd from 12:15 to 14:15 at position #456 in the category of Diagnostic Bacteriology III.
http://nanologix.com/news/poster-e-coli-0157.pdf
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B
Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
June 1, 2017
NanoLogix TB Detection Technology Use on Africa Project Increases
NanoLogix is pleased to announce that this week they shipped a new order for their TB Diagnostic test kits for use on an Africa research project funded by the National Institutes of Health, (NIH) the National Institute of Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation, with other funding from US and foreign Government agencies.
This is the third order since April on the Africa Project. NanoLogix was informed that in addition to the two sizes of kits sold in this order (150 mm and 100 mm), NanoLogix should prepare to supply two additional sizes of TB detection kits and also to significantly scale up TB kit production to satisfy projected needs.
For reference from an earlier update: "The technology used in the NanoLogix TB Test Kit is our BNP sandwiched-membrane technology. The use of the TB kit is to provide evidence of the presence of active (live) TB bacteria in a patient sample in 4-6 days rather than 3-5 weeks or more. The results from the NanoLogix TB tests are then processed through PCR (DNA testing) and other means to further define the identity of the TB. The original research paper citing the detection results and potential of pairing the NanoLogix technology with other technologies is available through this link:
https://www.omicsonline.org/1948-5948/JMBT-04-147.digital/JMBT-04-147.html
Related to this work, NanoLogix has received a request to pursue development of an N-Assay modified ELISA for detection and identification of TB. We will be doing so upon receipt of sufficient funding for that goal."
May 19, 2017
NanoLogix N-Assay Bacteria Diagnostic Technology for E. coli limited abstract
Novel Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of E. coli O157:H7
Novel Immunoassay for E coli O157:H7
Researchers: Classified until June 2017
Introduction: E. coli O157:H7 is associated with enterohemorrhagic infections, and is a concern for healthcare providers, food-handlers, and daycare providers. Rapid identification of this pathogen is critical in cases of outbreaks, and empirical treatment with broad-spectrum antibiotics may lead to more severe disease. We have developed an assay that allows for the simultaneous identification of E. coli O157:H7 and determination of its antibiotic susceptibility.
Methods: N-ASSAY
Methods Details Classified until June 2017
Results: O157:H7 was detected at and above 10^6 bacteria/ml following a 30-minute incubation, with no interference by other tested bacteria. By increasing the incubation time to 6 hours, the sensitivity of the test increased to 10^1 bacteria/ml. In addition, incubation with ceftriaxone during this six-hour time period showed inhibition of growth.
Summary: This assay allows for the rapid detection of a high inoculum of E. coli O157:H7, and sensitivity is increased following a six-hour incubation. Importantly, antibiotic susceptibility may be determined during this six-hour incubation.
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
May 8, 2017
Additional TB Test Kits ordered for Third World Gates Foundation Project
NanoLogix is pleased to announce that they have just (8 May 2017) received a new order for double the amount of their TB Diagnostic test kits delivered in April for use on a Third World research project funded by the National Institutes of Health, (NIH) the National Institute of Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation, with other funding from foreign Government agencies.
Since the request from the project representative stated that it is imperative the kits be delivered as soon as possible, NanoLogix is shipping the kits for Wednesday delivery. While the total sales amounts for the TB kits is in the thousands of dollars, Nanologix hopes the sales for use in this and other related TB projects will grow significantly.
The technology used in the NanoLogix TB Test Kit is our BNP sandwiched-membrane technology. The use of the TB kit is to provide evidence of the presence of active (live) TB bacteria in a patient sample in 4-6 days rather than 3-5 weeks or more. The results from the NanoLogix TB tests are then processed through PCR (DNA testing) and other means to further define the identity of the TB. The original research paper citing the detection results and potential of pairing the NanoLogix technology with other technologies is available through this link:
https://www.omicsonline.org/1948-5948/JMBT-04-147.digital/JMBT-04-147.html
Related to this work, NanoLogix has received a request to pursue development of an N-Assay modified ELISA for detection and identification of TB. We will be doing so upon receipt of sufficient funding for that goal.
In other news, patent work on either/both FlatPack and N-Assay patent applications has reached the stage where final examinations have been requested in Mexico, Canada, South Korea, and Brazil. Notification of FlatPack Patent Grant was received last week from Chile.
May 4, 2017
TB test Kits for use in Third World Gates Foundation Project
NanoLogix is pleased to elaborate further on an item of note from last month's announcement regarding shipment of TB Diagnostic kits to a Third World Research Project. The Company has sold and shipped their TB Diagnostic test kits for use on a Third World research project funded by the National Institutes of Health, (NIH) the National Institute of Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation, with other funding from foreign Government agencies.
Three reasons exist for this announcement. The first is to inform the public that whenever we released previous news where we were either named as being associated in research and development by an entity such as the US EPA or the University of Texas Health Science Center in Houston, or were cited in a research paper dealing with our technology by Battelle Biomedical Research Center in Ohio, those entities were all harassed by persons claiming to be NanoLogix shareholders who demanded to know the nature of the business relationships between the entities and NanoLogix and who asked for insider information regarding the status of the ongoing research. Those harassing efforts nearly destroyed the ongoing business relationships NanoLogix was truly privileged to have with those organizations. In this case anyone pursuing the same tact will come up against some very non-receptive forces.
The second is to demonstrate that we at NanoLogix had a goal, and that was to develop and provide to the world, diagnostic and research technologies that are premier and second to none, to create jobs in the rust belt area of northeast Ohio where the mindset of the area is steel mills, auto manufacturing, and low tech service jobs.
The third is to call attention to the facts that we, being a penny stock company, are considered the lowest of the low for investment. We are ignored by brokerages, especially ignored by the local media, and scorned by the investment community in general. Oddly enough, as ignored as we've been, we have still developed customized versions of our new N-Assay modified ELISA rapid bacteria diagnostic for one of the World's largest medical technology companies (under a very strong non-disclosure agreement), worked with the US EPA on developing tests for drinking and source waters, and had our technology presented as the fastest, most accurate and sensitive bacteria diagnostic test in the world. In addition, we've sold large numbers of proprietary packed FlatPacked petri plates in the USA and around the world for use in everything from simple quality control, food processing monitoring, soil testing, cosmetics and personal care products testing, environmental testing for post-flood contamination, water quality analysis, biodefense (we think, but classified), university research, and tens of thousands of users through Amazon and EBay for varied uses.
...and now we've sold TB diagnostics for use on a project funded by whom...?
Our share price and company are under attack by sick manipulators who only hurt dedicated shareholders. We as a company will survive and prosper.
We will expand our facilities as soon as feasible for increased FlatPack and N-Assay production, and are exploring relocating to a different state where we can be considered as bringing a benefit to the area.
Apr. 28, 2017
NanoLogix N-Assay Bacteria Diagnostic Technology for Rare Deinococcus Bacteria to be presented at AACC Annual Meeting in San Diego:
NanoLogix is pleased to announce that the N-Assay Bacteria Diagnostic, recently configured for detection and identification of a rare Deinococcus bacteria species will be presented in poster format at the American Association for Clinical Chemistry (AACC) 69th Annual Scientific Meeting and Clinical Lab Expo, to be held at the San Diego Convention Center in San Diego, California from July 30th through August 3rd, 2017. Dr. Jonathan Faro, MD, PhD and others associated with the development will be present for the poster session.
NanoLogix personnel are exploring the potential of staffing an exhibit booth at the event to display both the new modified-ELISA N-Assay diagnostic kit and also the FlatPack extended shelf life technology for petri plates.
The N-Assay Diagnostic furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus.
The published research results may be accessed through this link:
http://dx.doi.org/10.1155/2016/5293034
The AACC Deinococcus poster presentation illustrates how the N-Assay reduces the detection and identification times from roughly two weeks to a few days, with improved sensitivities over any other known test method.
Further information as to poster display and potential exhibit booth location will be made available in the near future when supplied to us by the AACC. Currently, general information for the event may be found by following this link:
https://www.aacc.org/meetings-and-events/2017-annual-meeting/clinical-lab-expo
The N-Assay Diagnostic for eColi will also be presented at the ASM Microbe 2017 in New Orleans June 1-5. Information for that event is available here:
https://www.asm.org/index.php/asm-microbe-2017
Apr. 4, 2017
NanoLogix has shipped TB test Kits for use in Third World Project
NanoLogix is pleased to announce items of note that have occurred this week. The first is that the Company has sold and shipped their TB Diagnostic test kits for use on a Third World research project funded by multiple US Federal and foreign Government agencies and a large international philanthropic organization. Once the project results are published we will be at liberty to elaborate further. The second item is that the Company today received the largest single delivery to date of petri plates for continued production of prepoured agar-filled FlatPacks, taking delivery of 150,000 sterilized petri plates.
Mar. 16, 2017
NanoLogix N-Assay Bacteria Diagnostic Technology for E. coli to be presented at June ASM Annual Meeting in New Orleans:
NanoLogix is pleased to announce that the N-Assay Bacteria Diagnostic, newly configured for E. coli will be presented in poster format at the American Society for Microbiology ASM Microbe 2017 to be held at the Ernest N. Morial Convention Center in New Orleans, Louisiana from June 1st through 5th. Dr. Sebastian Faro, MD, PhD and others associated with the development will be present for the poster session.
NanoLogix personnel are planning to staff an exhibit booth at the event to display both the Company-offered FlatPack for petri plates and the new N-Assay diagnostic. The FlatPack technology is becoming the premier petri plate storage method for those interested in long life room-temperature storage of prepared agar, with basic poured agars usable in as-new condition after 2-4 years of non-refrigerated storage. The NanoLogix FlatPack is available through www.nanologix.com and also on Amazon.com through two companies --- Evviva Scientific and Diamante Scientific.
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
Further information as to poster display and exhibit booth location will be made available in the near future when supplied to us by the ASM.
Mar. 2, 2017
NanoLogix is pleased to present a further update on the N-Assay Bacteria Diagnostic Technology:
After testing with customized N-Assay kits we supplied in January, the large medical technology client referenced in earlier updates has requested quotes from NanoLogix for expansion and further development using the N-Assay technology to detect additional bacteria species and genera.
Nanologix personnel and associates are excited to work with one of the World's largest medical companies on these N-Assay customizations. Due to a confidentiality agreement with our client, we cannot currently disclose the client identity.
There still remains the step of an independent time and sensitivity study for NanoLogix prior to marketing and sales for clinical use of the N-Assay. Personnel at a number of hospitals are reviewing potential study participation.
Jan. 9, 2017
NanoLogix is pleased to present a brief update on the N-Assay Bacteria Diagnostic Technology:
The N-Assay takes its place on our FDA medical device listing:
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm?lid=469637&lpcd=LIB
There is the remaining step of an independent time and sensitivity study for NanoLogix prior to marketing and sales for clinical use of the N-Assay.
NanoLogix has supplied all of the initially contracted and customized N-Assay kits to our multi-billion dollar medical technology client and we are awaiting results of their global testing.
Dec. 20, 2016
NanoLogix is pleased to announce the following Update:
The Company has narrowed its selection of buildings to use as a larger production facility in northeast Ohio. Two existing buildings are now under consideration to house NanoLogix production for both petri plates and for production of the new N-Assay ELISA-based rapid bacteria diagnostic. The projected expenditure for establishing N-Assay production and increasing petri plate production is roughly $900,000 for production equipment, $125,000 for the construction of two separate 70' X 30' production cleanrooms, and $40,000 for additional equipment such as forklifts.
This expansion is projected to result in market share increase for petri plate sales due to markedly improved economies of scale, and position NanoLogix with a significant production capability for the new N-Assay modified ELISA comprehensive bacteria diagnostic kit. The Company expects the expansion will result in ten additional jobs starting with the delivery and setup of the production equipment in 2017 and another ten positions upon expansion of N-Assay sales.
Over the coming six months we expect to finance the expansion through a combination of increasing revenue from sales of both product lines and fundraising through our current SEC Regulation D, Rule 506 offering for private placement sales of shares.
Any share issuance financing for this expansion is being structured primarily, but not solely, through a series of equity tranches and stock warrants. Using this method, the Company hopes to keep stock dilution to a minimum and will proceed with the interests of the shareholders in mind, including extending the timeline for expansion as necessary if equity costs are not favorable to NanoLogix.
The Company is preparing to seek licensees in Europe and Hong Kong for production of FlatPack Petri Plates under the recent EU FlatPack patent approval.
In response to queries coming to our office regarding our customization of the N-Assay for a multibillion medical technology company: we have sold 600+ of the N-Assay to them and will be supplying more in addition to further customization for other bacteria in 2017. As our arrangement with the client is CONFIDENTIAL, we will not be releasing their name.
Merry Christmas from Carol, Debby, Kim, Travis, Bret and all
Dec. 6, 2016
NanoLogix is pleased to announce the following Update:
The Company is currently searching for a larger production facility in northeast Ohio. In the past three weeks NanoLogix management and production staff have viewed, toured, and measured four separate sites to ascertain site suitability for relocating and expanding NanoLogix production for both petri plates and for production of the new N-Assay ELISA-based rapid bacteria diagnostic.
The new sites being surveyed range from 10,000 square feet to 22,000 square feet, three to seven times the size of our current facility. All sites viewed offer additional square footage for further expansion as required.
NanoLogix is also in the process of specifying and ordering new equipment for the production of both petri plates and the new N-Assay.
The two petri plate filling machines that have been configured for order are both OnlineEngineering MultiDish Model 968 with ancillary equipment. The Model 968 is capable of filling 9,600 plates per hour, so the two machines should be capable of meeting production needs for the forseeable future. Further information on the equipment can be found at: www.online-engineering.com
The N-Assay equipment currently being researched and specified are automatic pippetting machines for application of antibodies, etc., to the ELISA plates used for this revolutionary rapid bacteria diagnostic technology.
The two technologies will be housed in separate modular cleanrooms in order to comply with specific FDA requirements for manufacturing of each product.
The projected timeline for delivery and assembly of modular cleanrooms, the OnlineEngineering equipment, and the automated pippetting machines is sometime in the second quarter of 2017, while configuration of whichever of the candidate sites is chosen is projected to begin in the first quarter of 2017.
Petri plate production is currently in Hubbard, Ohio, while N-Assay production is in Houston, Texas. N-Assay production in Ohio is projected to begin in the second quarter of 2017.
------------------------------------------------------------------------------------------------------------------------------
Updates are available by signing up for eNews on the company's homepage at nanologix.com.
So I guess NanoLogix does not have a booth at ASM Microbe 2017?
http://microbe2017.mapyourshow.com/7_0/alphalist.cfm?alpha=N&CFID=16943499&CFTOKEN=ec8607b129d8d441-FF0407AF-C146-D3F4-7E2D21A55B32E085
Rest in peace, Waitedog. LOL...I say it affectionately now. I trust you are with Jesus now, my friend.
Sleepin'
Company Updates
May 19, 2017
NanoLogix N-Assay Bacteria Diagnostic Technology for E. coli limited abstract
Novel Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of E. coli O157:H7
Novel Immunoassay for E coli O157:H7
Researchers: Classified until June 2017
Introduction: E. coli O157:H7 is associated with enterohemorrhagic infections, and is a concern for healthcare providers, food-handlers, and daycare providers. Rapid identification of this pathogen is critical in cases of outbreaks, and empirical treatment with broad-spectrum antibiotics may lead to more severe disease. We have developed an assay that allows for the simultaneous identification of E. coli O157:H7 and determination of its antibiotic susceptibility.
Methods: N-ASSAY
Methods Details Classified until June 2017
Results: O157:H7 was detected at and above 10^6 bacteria/ml following a 30-minute incubation, with no interference by other tested bacteria. By increasing the incubation time to 6 hours, the sensitivity of the test increased to 10^1 bacteria/ml. In addition, incubation with ceftriaxone during this six-hour time period showed inhibition of growth.
Summary: This assay allows for the rapid detection of a high inoculum of E. coli O157:H7, and sensitivity is increased following a six-hour incubation. Importantly, antibiotic susceptibility may be determined during this six-hour incubation.
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
May 8, 2017
Additional TB Test Kits ordered for Third World Gates Foundation Project
NanoLogix is pleased to announce that they have just (8 May 2017) received a new order for double the amount of their TB Diagnostic test kits delivered in April for use on a Third World research project funded by the National Institutes of Health, (NIH) the National Institute of Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation, with other funding from foreign Government agencies.
Since the request from the project representative stated that it is imperative the kits be delivered as soon as possible, NanoLogix is shipping the kits for Wednesday delivery. While the total sales amounts for the TB kits is in the thousands of dollars, Nanologix hopes the sales for use in this and other related TB projects will grow significantly.
The technology used in the NanoLogix TB Test Kit is our BNP sandwiched-membrane technology. The use of the TB kit is to provide evidence of the presence of active (live) TB bacteria in a patient sample in 4-6 days rather than 3-5 weeks or more. The results from the NanoLogix TB tests are then processed through PCR (DNA testing) and other means to further define the identity of the TB. The original research paper citing the detection results and potential of pairing the NanoLogix technology with other technologies is available through this link:
https://www.omicsonline.org/1948-5948/JMBT-04-147.digital/JMBT-04-147.html
Related to this work, NanoLogix has received a request to pursue development of an N-Assay modified ELISA for detection and identification of TB. We will be doing so upon receipt of sufficient funding for that goal.
In other news, patent work on either/both FlatPack and N-Assay patent applications has reached the stage where final examinations have been requested in Mexico, Canada, South Korea, and Brazil. Notification of FlatPack Patent Grant was received last week from Chile.
May 4, 2017
TB test Kits for use in Third World Gates Foundation Project
NanoLogix is pleased to elaborate further on an item of note from last month's announcement regarding shipment of TB Diagnostic kits to a Third World Research Project. The Company has sold and shipped their TB Diagnostic test kits for use on a Third World research project funded by the National Institutes of Health, (NIH) the National Institute of Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation, with other funding from foreign Government agencies.
Three reasons exist for this announcement. The first is to inform the public that whenever we released previous news where we were either named as being associated in research and development by an entity such as the US EPA or the University of Texas Health Science Center in Houston, or were cited in a research paper dealing with our technology by Battelle Biomedical Research Center in Ohio, those entities were all harassed by persons claiming to be NanoLogix shareholders who demanded to know the nature of the business relationships between the entities and NanoLogix and who asked for insider information regarding the status of the ongoing research. Those harassing efforts nearly destroyed the ongoing business relationships NanoLogix was truly privileged to have with those organizations. In this case anyone pursuing the same tact will come up against some very non-receptive forces.
The second is to demonstrate that we at NanoLogix had a goal, and that was to develop and provide to the world, diagnostic and research technologies that are premier and second to none, to create jobs in the rust belt area of northeast Ohio where the mindset of the area is steel mills, auto manufacturing, and low tech service jobs.
The third is to call attention to the facts that we, being a penny stock company, are considered the lowest of the low for investment. We are ignored by brokerages, especially ignored by the local media, and scorned by the investment community in general. Oddly enough, as ignored as we've been, we have still developed customized versions of our new N-Assay modified ELISA rapid bacteria diagnostic for one of the World's largest medical technology companies (under a very strong non-disclosure agreement), worked with the US EPA on developing tests for drinking and source waters, and had our technology presented as the fastest, most accurate and sensitive bacteria diagnostic test in the world. In addition, we've sold large numbers of proprietary packed FlatPacked petri plates in the USA and around the world for use in everything from simple quality control, food processing monitoring, soil testing, cosmetics and personal care products testing, environmental testing for post-flood contamination, water quality analysis, biodefense (we think, but classified), university research, and tens of thousands of users through Amazon and EBay for varied uses.
...and now we've sold TB diagnostics for use on a project funded by whom...?
Our share price and company are under attack by sick manipulators who only hurt dedicated shareholders. We as a company will survive and prosper.
We will expand our facilities as soon as feasible for increased FlatPack and N-Assay production, and are exploring relocating to a different state where we can be considered as bringing a benefit to the area.
Apr. 28, 2017
NanoLogix N-Assay Bacteria Diagnostic Technology for Rare Deinococcus Bacteria to be presented at AACC Annual Meeting in San Diego:
NanoLogix is pleased to announce that the N-Assay Bacteria Diagnostic, recently configured for detection and identification of a rare Deinococcus bacteria species will be presented in poster format at the American Association for Clinical Chemistry (AACC) 69th Annual Scientific Meeting and Clinical Lab Expo, to be held at the San Diego Convention Center in San Diego, California from July 30th through August 3rd, 2017. Dr. Jonathan Faro, MD, PhD and others associated with the development will be present for the poster session.
NanoLogix personnel are exploring the potential of staffing an exhibit booth at the event to display both the new modified-ELISA N-Assay diagnostic kit and also the FlatPack extended shelf life technology for petri plates.
The N-Assay Diagnostic furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus.
The published research results may be accessed through this link:
http://dx.doi.org/10.1155/2016/5293034
The AACC Deinococcus poster presentation illustrates how the N-Assay reduces the detection and identification times from roughly two weeks to a few days, with improved sensitivities over any other known test method.
Further information as to poster display and potential exhibit booth location will be made available in the near future when supplied to us by the AACC. Currently, general information for the event may be found by following this link:
https://www.aacc.org/meetings-and-events/2017-annual-meeting/clinical-lab-expo
The N-Assay Diagnostic for eColi will also be presented at the ASM Microbe 2017 in New Orleans June 1-5. Information for that event is available here:
https://www.asm.org/index.php/asm-microbe-2017
Apr. 4, 2017
NanoLogix has shipped TB test Kits for use in Third World Project
NanoLogix is pleased to announce items of note that have occurred this week. The first is that the Company has sold and shipped their TB Diagnostic test kits for use on a Third World research project funded by multiple US Federal and foreign Government agencies and a large international philanthropic organization. Once the project results are published we will be at liberty to elaborate further. The second item is that the Company today received the largest single delivery to date of petri plates for continued production of prepoured agar-filled FlatPacks, taking delivery of 150,000 sterilized petri plates.
Mar. 16, 2017
NanoLogix N-Assay Bacteria Diagnostic Technology for E. coli to be presented at June ASM Annual Meeting in New Orleans:
NanoLogix is pleased to announce that the N-Assay Bacteria Diagnostic, newly configured for E. coli will be presented in poster format at the American Society for Microbiology ASM Microbe 2017 to be held at the Ernest N. Morial Convention Center in New Orleans, Louisiana from June 1st through 5th. Dr. Sebastian Faro, MD, PhD and others associated with the development will be present for the poster session.
NanoLogix personnel are planning to staff an exhibit booth at the event to display both the Company-offered FlatPack for petri plates and the new N-Assay diagnostic. The FlatPack technology is becoming the premier petri plate storage method for those interested in long life room-temperature storage of prepared agar, with basic poured agars usable in as-new condition after 2-4 years of non-refrigerated storage. The NanoLogix FlatPack is available through www.nanologix.com and also on Amazon.com through two companies --- Evviva Scientific and Diamante Scientific.
The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.
Further information as to poster display and exhibit booth location will be made available in the near future when supplied to us by the ASM.
Mar. 2, 2017
NanoLogix is pleased to present a further update on the N-Assay Bacteria Diagnostic Technology:
After testing with customized N-Assay kits we supplied in January, the large medical technology client referenced in earlier updates has requested quotes from NanoLogix for expansion and further development using the N-Assay technology to detect additional bacteria species and genera.
Nanologix personnel and associates are excited to work with one of the World's largest medical companies on these N-Assay customizations. Due to a confidentiality agreement with our client, we cannot currently disclose the client identity.
There still remains the step of an independent time and sensitivity study for NanoLogix prior to marketing and sales for clinical use of the N-Assay. Personnel at a number of hospitals are reviewing potential study participation.
Jan. 9, 2017
NanoLogix is pleased to present a brief update on the N-Assay Bacteria Diagnostic Technology:
The N-Assay takes its place on our FDA medical device listing:
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm?lid=469637&lpcd=LIB
There is the remaining step of an independent time and sensitivity study for NanoLogix prior to marketing and sales for clinical use of the N-Assay.
NanoLogix has supplied all of the initially contracted and customized N-Assay kits to our multi-billion dollar medical technology client and we are awaiting results of their global testing.
Dec. 20, 2016
NanoLogix is pleased to announce the following Update:
The Company has narrowed its selection of buildings to use as a larger production facility in northeast Ohio. Two existing buildings are now under consideration to house NanoLogix production for both petri plates and for production of the new N-Assay ELISA-based rapid bacteria diagnostic. The projected expenditure for establishing N-Assay production and increasing petri plate production is roughly $900,000 for production equipment, $125,000 for the construction of two separate 70' X 30' production cleanrooms, and $40,000 for additional equipment such as forklifts.
This expansion is projected to result in market share increase for petri plate sales due to markedly improved economies of scale, and position NanoLogix with a significant production capability for the new N-Assay modified ELISA comprehensive bacteria diagnostic kit. The Company expects the expansion will result in ten additional jobs starting with the delivery and setup of the production equipment in 2017 and another ten positions upon expansion of N-Assay sales.
Over the coming six months we expect to finance the expansion through a combination of increasing revenue from sales of both product lines and fundraising through our current SEC Regulation D, Rule 506 offering for private placement sales of shares.
Any share issuance financing for this expansion is being structured primarily, but not solely, through a series of equity tranches and stock warrants. Using this method, the Company hopes to keep stock dilution to a minimum and will proceed with the interests of the shareholders in mind, including extending the timeline for expansion as necessary if equity costs are not favorable to NanoLogix.
The Company is preparing to seek licensees in Europe and Hong Kong for production of FlatPack Petri Plates under the recent EU FlatPack patent approval.
In response to queries coming to our office regarding our customization of the N-Assay for a multibillion medical technology company: we have sold 600+ of the N-Assay to them and will be supplying more in addition to further customization for other bacteria in 2017. As our arrangement with the client is CONFIDENTIAL, we will not be releasing their name.
Merry Christmas from Carol, Debby, Kim, Travis, Bret and all
Dec. 6, 2016
NanoLogix is pleased to announce the following Update:
The Company is currently searching for a larger production facility in northeast Ohio. In the past three weeks NanoLogix management and production staff have viewed, toured, and measured four separate sites to ascertain site suitability for relocating and expanding NanoLogix production for both petri plates and for production of the new N-Assay ELISA-based rapid bacteria diagnostic.
The new sites being surveyed range from 10,000 square feet to 22,000 square feet, three to seven times the size of our current facility. All sites viewed offer additional square footage for further expansion as required.
NanoLogix is also in the process of specifying and ordering new equipment for the production of both petri plates and the new N-Assay.
The two petri plate filling machines that have been configured for order are both OnlineEngineering MultiDish Model 968 with ancillary equipment. The Model 968 is capable of filling 9,600 plates per hour, so the two machines should be capable of meeting production needs for the forseeable future. Further information on the equipment can be found at: www.online-engineering.com
The N-Assay equipment currently being researched and specified are automatic pippetting machines for application of antibodies, etc., to the ELISA plates used for this revolutionary rapid bacteria diagnostic technology.
The two technologies will be housed in separate modular cleanrooms in order to comply with specific FDA requirements for manufacturing of each product.
The projected timeline for delivery and assembly of modular cleanrooms, the OnlineEngineering equipment, and the automated pippetting machines is sometime in the second quarter of 2017, while configuration of whichever of the candidate sites is chosen is projected to begin in the first quarter of 2017.
Petri plate production is currently in Hubbard, Ohio, while N-Assay production is in Houston, Texas. N-Assay production in Ohio is projected to begin in the second quarter of 2017.
---------------------------------------------------------------------------------------------------------------------------------------
Updates are available by signing up for eNews on the company's homepage at nanologix.com.
Indeed...welcome, Tradefm. :) EOM
Okay, but it's another patent application whose patent application number shows its eventual abandonment.
06-18-2015 Mail Abandonment for Failure to Respond to Office Action
06-15-2015 Aband. for Failure to Respond to O. A.
12-09-2014 Mail Final Rejection (PTOL - 326)
12-08-2014 Final Rejection
07-03-2014 Affidavit(s) (Rule 131 or 132) or Exhibit(s) Received
07-08-2014 Date Forwarded to Examiner
07-03-2014 Response after Non-Final Action
04-03-2014 Mail Non-Final Rejection
03-23-2014 Non-Final Rejection
08-27-2013 Case Docketed to Examiner in GAU
01-09-2013 Date Forwarded to Examiner
01-08-2013 Request for Continued Examination (RCE)
01-09-2013 Disposal for a RCE / CPA / R129
01-08-2013 Workflow - Request for RCE - Begin
12-10-2012 Mail Advisory Action (PTOL - 303)
12-06-2012 Advisory Action (PTOL-303)
12-06-2012 Date Forwarded to Examiner
11-30-2012 Response after Final Action
11-14-2012 Mail Interview Summary - Applicant Initiated - Personal
11-13-2012 Interview Summary- Applicant Initiated
11-13-2012 Interview Summary - Applicant Initiated - Personal
10-23-2012 Mail Final Rejection (PTOL - 326)
10-19-2012 Final Rejection
09-11-2012 Information Disclosure Statement considered
09-17-2012 Date Forwarded to Examiner
09-10-2012 Response after Non-Final Action
09-11-2012 Electronic Information Disclosure Statement
09-11-2012 Information Disclosure Statement (IDS) Filed
06-12-2012 Mail Non-Final Rejection
06-08-2012 Non-Final Rejection
01-29-2010 Information Disclosure Statement considered
10-04-2011 Information Disclosure Statement considered
05-10-2012 Date Forwarded to Examiner
05-04-2012 Response to Election / Restriction Filed
04-26-2012 Mail Restriction Requirement
04-24-2012 Restriction/Election Requirement
03-09-2012 Case Docketed to Examiner in GAU
01-22-2012 Case Docketed to Examiner in GAU
10-04-2011 Electronic Information Disclosure Statement
10-04-2011 Information Disclosure Statement (IDS) Filed
08-31-2010 Change in Power of Attorney (May Include Associate POA)
08-26-2010 Correspondence Address Change
08-18-2010 Mail Pre-Exam Notice
07-30-2010 Case Docketed to Examiner in GAU
07-29-2010 PG-Pub Issue Notification
01-29-2010 Electronic Information Disclosure Statement
09-22-2009 Request for Foreign Priority (Priority Papers May Be Included)
05-13-2010 Application Dispatched from OIPE
03-16-2010 371 Completion Date
04-21-2010 Sent to Classification Contractor
04-21-2010 Filing Receipt
04-21-2010 Notice of DO/EO Acceptance Mailed
03-16-2010 Additional Application Filing Fees
03-16-2010 A statement by one or more inventors satisfying the requirement under 35 USC 115, Oath of the Applic
01-29-2010 Information Disclosure Statement (IDS) Filed
12-22-2009 Notice of DO/EO Missing Requirements Mailed
09-22-2009 Cleared by OIPE CSR
09-22-2009 IFW Scan & PACR Auto Security Review
09-22-2009 Initial Exam Team nn
https://portal.uspto.gov/pair/PublicPair
Appl. No.: 12/785180
Date Transaction Description
03-27-2013 Mail Express Abandonment (During Examination)
03-26-2013 Express Abandonment (during Examination)
03-24-2013 Letter of Express Abandonment Filed
01-24-2013 Mail Final Rejection (PTOL - 326)
01-22-2013 Final Rejection
12-20-2012 Date Forwarded to Examiner
12-17-2012 Response after Non-Final Action
09-20-2012 Mail Non-Final Rejection
09-18-2012 Non-Final Rejection
08-15-2012 Case Docketed to Examiner in GAU
08-15-2012 Case Docketed to Examiner in GAU
06-18-2012 Date Forwarded to Examiner
06-18-2012 Response to Election / Restriction Filed
06-06-2012 Mail Restriction Requirement
05-17-2012 Restriction/Election Requirement
09-10-2010 Information Disclosure Statement considered
02-07-2012 Information Disclosure Statement considered
02-07-2012 Electronic Information Disclosure Statement
02-07-2012 Information Disclosure Statement (IDS) Filed
01-09-2012 Preliminary Amendment
10-19-2011 Preliminary Amendment
09-10-2010 Electronic Information Disclosure Statement
09-10-2010 Information Disclosure Statement (IDS) Filed
09-09-2010 PG-Pub Issue Notification
09-03-2010 Case Docketed to Examiner in GAU
09-03-2010 Change in Power of Attorney (May Include Associate POA)
09-01-2010 Correspondence Address Change
08-19-2010 Mail Pre-Exam Notice
06-29-2010 Application Dispatched from OIPE
06-03-2010 Application Is Now Complete
06-03-2010 Sent to Classification Contractor
06-03-2010 Filing Receipt
05-25-2010 Cleared by OIPE CSR
05-21-2010 IFW Scan & PACR Auto Security Review
05-21-2010 Initial Exam Team nn
I stand corrected. Thank you, EI. EOM